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CHAPTER I 
 
INTRODUCTION 
Proteomic difference testing has emerged as a critical tool in biomedical research for elucidating 
the molecular mechanisms underlying complex biological pathways. Biomarker detection, drug 
discovery and studies of variations in biological proteomes provide instances of research areas 
which would benefit from an enhancement in the ability to detect changes in protein abundance. 
While liquid chromatography tandem mass spectrometry (LC-MS/MS) (1, 2) has successfully 
been utilized to achieve this, many challenges remain to be addressed.    
Two separate experimental approaches can be used to achieve protein quantitation: the 
first one involves isotope labeling (3-6) and the second approach utilizes label-free shotgun LC-
MS/MS (7-10). While isotope labeling can provide more reliable results, the tradeoff is higher 
experimental cost and labor.  Label-free shotgun LC-MS/MS reduces the complexity of 
experimental data generation while being statistically less powerful and prone to higher error 
rates than isotopic labeling.  Given that reduction of experimental complexity is highly desirable 
in many situations, improvements in label-free LC-MS/MS difference testing are needed.   
Proteomic difference testing can be approached qualitatively (i.e. which proteins vary 
between different test cases) as well as quantitatively (i.e. how much does a specific protein vary 
under different conditions).  Label-free LC-MS/MS produces two fundamental types of data that 
can answer these questions: peptide precursor ion peak intensities and spectral counts of 
identified MS/MS spectra.  Both types of data can be used separately for qualitative and 
quantitative difference testing. A myriad of different experimental and statistical techniques have 
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been developed in recent years to harness these two data types (3-10).  However, spectral counts 
and precursor intensities follow fundamentally different statistical distributions that have their 
own inherent strengths and weaknesses when applied to difference testing, and neither data type 
can be considered exclusively superior to the other for the purpose of difference testing.  Ideally, 
the information provided by both spectral counts and precursor intensities can be utilized in 
concert to balance their respective strengths and drawbacks.   
We hypothesized that a statistical test integrating spectral count data with precursor 
intensity data could result in improved overall test results.  To test this hypothesis, we developed 
a new tool called IDPQuantify.  IDPQuantify was developed with the following specific aims in 
mind:  
Specific Aim I.  Evaluate the performance of statistical difference testing using precursor 
intensities or spectral counts.  In particular, we were interested in establishing the degree of 
independence (orthogonality vs. mutual information) between statistical difference tests using 
either count data or intensity data alone.      
Specific Aim II.  Evaluate a new statistical model for label-free qualitative difference 
testing that combines precursor ion intensities with spectral count data.  The model uses Fisher‟s 
Method for combining p-values into a single p-value using the p-values from a precursor 
intensities-based test and a spectral count-based test.       
Specific Aim III.  Establish the validity of conducting difference testing at the peptide 
group-level.  Protein difference testing is typically performed at the protein-level.  Peptide group 
difference testing segregates peptides into peptide groups that are associated with a single protein 
group or shared across multiple protein groups.  We wanted to show that difference testing at the 
peptide group-level is effective at reducing the noise associated with shared peptides. 
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This study is structured as follows:  In Chapter II, we review the published literature on 
label-free LC-MS/MS quantitation and the relationship between spectral count data and 
precursor ion intensities.  In Chapter III, IDPQuantify and our combined model are introduced 
and defined.  IDPQuantify‟s features are explained along with our combined statistical model.  
The existing statistical tests are used to evaluate and compare the performance of our combined 
model as well as assess the viability of peptide group-level difference testing.  Chapter IV 
introduces our evaluation data set.  The results of the statistical test comparative analysis are 
described and discussed.  Chapter V contains the final conclusions of this study and future 
directions. 
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CHAPTER II 
 
BACKGROUND AND SIGNIFICANCE 
 
Proteomic difference testing falls into two general categories:  qualitative difference testing 
(which proteins changed in abundance) and quantitative difference testing (how much did the 
proteins change in abundance).  When LC-MS/MS data is used to conduct the difference testing, 
the data available for difference testing also falls into two general categories:  MS/MS spectral 
counts and MS precursor ion intensities.  When isotopic or mass-tag labeling is used, the internal 
standard‟s signal is also available.  Label-free quantitation lacks an internal standard signal but 
remains appealing due to its lower cost and ease of implementation.  As such, improving 
quantitative methods which eliminate the need for internal standards by relying exclusively on 
spectral counts or precursor ion intensities is highly desirable.   
The choice of one of these metrics (spectral counts or precursor ion intensities) over the 
other for label-free quantitation depends on the type of difference testing question under 
investigation (which proteins changed vs. what was the fold change).  But neither spectral counts 
nor precursor ions can be considered the clearly superior choice of data for either qualitative or 
quantitative difference testing.  In 2004, Liu et al. established the viability of spectral count totals 
(per protein) as a statistically useful metric that was both randomly sampled and directly 
proportional to protein abundance over two orders of magnitude (10).   
A 2005 study by Old et al. (11) investigated how precursor ion intensities and spectral 
counts differ in their abilities to detect the identities of the proteins which changed in abundance 
and what was the fold change across cohorts. Using isotopic labeling as their control, Old et al. 
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found that spectral counts and precursor intensities both perform comparably for either the 
qualitative or quantitative forms of difference testing.  But they also observed that spectral count-
based methods tended to be more reliable for answering the question of which proteins changed 
in abundance, whereas precursor intensities were generally better for determining the fold-
change in abundance between cohorts.  This is in keeping with a more recent study by Park that 
also found better agreement between the fold-changes found using LC-MS precursor peaks 
versus spectral counts (12). 
The comparable, but still distinct, performance of spectral counts and precursor ion 
intensities for quantitation is also reflected in differences in their dynamic ranges and 
vulnerabilities to error.  For instance, Old et al. found that both spectral count and precursor 
intensity methods suffered from erroneous fold change estimates for low abundance proteins(11).  
Spectral counts suffered from a lack of continuity as counts approached zero in one or both 
cohorts, leading to an overestimation of ratios.  Precursor intensities, on the other hand, tended to 
underestimate ratios for low intensity precursors due to baseline intensity noise contributing to 
precursor signals.   
On the high end of the abundance range, Old et al. found the most accurate fold-change 
estimates for proteins when measuring highly abundant proteins with large numbers of spectral 
counts in both cohorts(11).  At the same time, Old et al. found an under-sampling of spectral 
counts for the most abundant proteins which they attributed to the data dependent acquisition 
exclusion lists.  Precursor intensities may also become non-linear for the most abundant peptides 
when electrospray ionization is used, due, in part, to the impact of ion suppression (13).  
The correlation between spectral counts and precursor ion intensities for relative 
abundance measurements has also been investigated (16).  Using 
14
N/
15
N metabolic labeling as a 
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control, Zybailov et al. found a strong positive Pearson product moment correlation of 0.64 
between abundance ratios calculated using spectral counts vs. precursor intensities.  When 
minimum spectral count (per protein) filters and minimum precursor ion signal-to-noise filters 
were employed, the correlation was even stronger, highlighting the difficulties both spectral 
counts and precursor intensity methods face when dealing with less concentrated peptides.  Also 
similar to the findings of Old and others (14, 15), Zaibalov et al. found that spectral count-based 
methods were more reproducible and had a larger dynamic range than precursor intensity 
methods.  But the larger dynamic range of spectral counts was attributed, in part, to the 
respective zero-boundary issues (e.g. spectral count-based methods yielding higher ratios when 
one cohort has near-zero counts vs. baseline noise contributing to lower ratios when low 
abundant precursor ions are compared).  More recently, Park et al. also found that both spectral 
counts and LC-MS precursor intensities could be used for abundance ratio approximation, but 
they found precursor peak areas under the curve to be a more reliable approach than spectral 
counts (12). 
The larger dynamic range of protein abundance ratios when using spectral-count vs. 
precursor intensities observed by both Old et al. and Zybailov et al. also highlights the 
differences in the constraints required to conduct the different types of statistical tests available 
for count data vs. normally distributed area/volume data.  For example, when assessing how 
spectral counts compared to precursor intensities for qualitative difference testing, Old et al. used 
minimum thresholds for determining whether a protein was viable for statistical difference 
testing using either spectral counts or precursor intensities.  Proteins that had at least 4 spectra 
(found amongst all peptides across replicates) in either cohort were deemed viable for spectral 
count difference testing using a modified G-test.  But when precursor intensities were used, 
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Student‟s t-test was employed, and their methodology required proteins to have at least three 
peptides shared between cohorts for difference testing.  The threshold of four unpaired spectral 
counts per protein is much easier to meet than three shared peptides across cohorts, and thus 
nearly 10-fold more proteins were tested using spectral counts than were tested using precursor 
intensities.   
Not surprisingly, the range of ratios seen in proteins found to be differentially abundant 
using spectral counts, alone, was ~4 fold greater than the range of ratios in proteins found to be 
differentially abundant using precursor intensities alone (11).  So in addition to the tendency of 
spectral count to overestimate abundance ratios (due to zero-bound continuity issues), the larger 
range of ratios seen in proteins found to be differentially abundant using spectral counts is 
expected, given the much larger number of spectral count-based tests conducted.   
The distributions of spectral counts and precursor peak intensities are fundamentally 
different.  Precursor peak intensities are a measure of how much of a given peptide is observed.  
Intensities follow an exponential decay distribution within a given run but are, ideally, normally 
distributed across replicates for a given peptide (at a specific charge state).  Appropriate 
statistical tests for normally distributed data (e.g. Student‟s t-test) depend on repeated measures 
per cohort (at least three) in order to approximate both the mean and variance.  Spectral counts, 
on the other hand, are a measure of how frequently we observe a given protein‟s peptides.  Count 
data follows a Poisson distribution and can therefore be applied to non-parametric statistical tests 
such as Fisher‟s exact test and the G-test.  Non-parametric tests are potentially quite useful for 
proteomic LC-MS/MS data sets.  They are more robust against outliers compared to their 
parametric counter parts and because Fisher‟s exact test and the G-test do not require more than 
one replicate per cohort and are more robust against missing data.  Thus, the substantially larger 
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number of differentially abundant peptides identified by Old et al. when using spectral counts 
was indeed partially caused by the different thresholds employed for spectral counts and 
precursor intensities, but those different thresholds were reflective of the more relaxed 
constraints available to frequency-based statistical tests compared to the intensity-based 
parametric tests (16).   
Spectral counts are not exclusively applicable to non-parametric tests.  The Normalized 
Spectral Abundance Factor (NSAF), developed by Zybailov et al., first normalizes each protein‟s 
spectral counts by the length of the protein and penalizes the total spectral count for larger 
proteins due to the greater number of peptides generated by longer proteins (16).   The resulting 
Spectral Abundance Factor (SAF) for a given protein is further normalized to the entire data set 
by dividing the SAF by the sum of SAFs for all identified proteins to get the NSAF.   The natural 
log of these NSAF values turns out to be normally distributed, making parametric tests like 
Student‟s t-test available for spectral count data (16, 17).   
By using a normalization factor that takes into account the different sizes of proteins that 
could have generated the same peptides, the NSAF metric also begins to address another key 
challenge in quantitative proteomics:  how to account for shared peptides.  The “bottom up” 
approach of shotgun proteomics gathers data at the peptide level while researchers are interested 
in protein identification and quantitation.  This introduces multiple ambiguities in the 
interpretation of LC-MS/MS data.  Consider a peptide A that that could have come from two 
proteins of differing lengths:  protein 1 (longer) and protein 2.  If protein 1 and protein 2 were 
both at equal abundance we would expect the longer of the two to generate more peptides and 
contribute more spectral counts.  As such, if the spectral counts for peptide A are contributing to 
protein 1‟s total count, each individual spectral count is being drawn from a larger pool of 
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theoretical counts and should be given less weight than if the counts were being attributed to the 
shorter protein 2.  
  The original NSAF approach helped to address how to weight peptide spectral counts 
when attributing the same peptide‟s counts to proteins of differing lengths, but it left unresolved 
the issue of attributing the same spectral counts to multiple proteins.  By adding the spectral 
counts of shared peptides to each potential parent protein, we are assuming that each of those 
proteins contributed equal numbers of precursor ions to each identified MS/MS spectra, a clearly 
erroneous assumption.  The greater the number of proteins that could have contributed to a given 
peptide, the greater the ambiguity in the identity of the protein which contributed the peptide and 
the greater the number of extra counts that will be erroneously applied if  shared peptide counts 
are equally applied to all of the possible protein contributors.  For complex proteomes, shared 
peptides can be particularly troublesome.  The human genome, for instance, is estimated to have 
~1,000,000 protein isoforms, with 5-7 isoforms on average per open reading frame (18).  
Distinguishing between post-translationally modified proteins and their unmodified forms 
presents another source of shared peptide ambiguity.  And the lower the abundance of a given 
protein, the greater the relative error for each erroneously attributed spectral count.   
 The best way to deal with all of these complications arising from shared peptides 
remains an open area of research.  Zhang et al. recently compared the original NSAF method to 
several alternative approaches that accounted for shared peptides in the normalization process 
(19).  They found the normalized spectral counts from the original NSAF method to have the 
worst linearity due, in part, to the multiple counting of shared peptides causing a systematic 
overestimation of the concentrations of less concentrated proteins.   The top performing method 
they observed for addressing shared peptides involved distributing all of the spectral counts from 
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shared peptides to their potential parent proteins.  The fraction of the shared spectral count that 
each potential parent protein receives is equal to the fraction of spectral counts from unshared 
peptides that a given protein received amongst the total number unshared spectral counts for that 
set of potential parent proteins. Zhang et al. (19) also evaluated the approach by simply 
discarding shared peptides from consideration.  While this method had a superior dynamic range 
to that of the original NSAF method, it also tended to underestimate less abundant proteins.   
 Usaite et al. (15) also found a loss of linearity for spectral counts from low abundance 
proteins and demonstrated that shared peptides give much more variable and unreliable 
abundance ratios if the parent proteins are expressed at different levels (15).  Using the spectral 
count data from two highly homologous proteins expressed at different levels, they calculated the 
abundance ratios for each separate peptide from the two proteins (using the original NSAF 
method for normalization).  The abundance ratios of the unshared peptides clustered around two 
distinct population levels, whereas the shared peptides gave highly variable ratios.  When they 
statistically difference tested several thousand proteins from a yeast proteome between Wild 
Type (WT) and Knockout (KO) cohorts, they found that 12% of the proteins had statistically 
different results depending on whether or not shared peptides were used.   
An early metric similar to the NSAF, the Protein Abundance Index (PAI), was based not 
on spectral counts, but on the percentage of a protein‟s theoretical sequence that was identified in 
the runs.  The PAI normalization factor simply divided the total number of unique peptides 
measured for a given protein by the theoretical number of unique peptides that could be 
generated from the protein (20).  This led to the creation of the Exponentially Modified Protein 
Abundance Index (emPAI) by Ishihama et al. for use with precursor intensity-based quantitation 
based on the observation of a linear relationship between the PAI values and the natural log of 
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protein abundances (21).  As would be expected, they also observed a linear relationship between 
a protein‟s spectral counts and its abundance but also observed that the number of unique 
peptides identified for a protein was linearly correlated with the log of the protein‟s abundance, 
suggesting a linear increase in observed sequence coverage corresponds to an exponential 
increase in protein abundance.  The emPAI index is the exponential of the PAI and was shown to 
be strongly correlated with protein abundance (2.1): 
 
 emPAI = 10
PAI – 1   (2.1) 
 
 Interestingly, while sequence coverage may be the highest for the most abundant 
proteins, Ishihara et al. also found a reduced correlation between protein abundance and the 
emPAI metric for the most abundant proteins, highlighting how the most abundant proteins may 
be the easiest to identify but not necessarily the easiest to quantify (21).     
A third normalization technique, the Protein Abundance Factor (PAF) developed by Link 
et al., constitutes a mix of the NSAF and emPAI normalization techniques by factoring in both 
the extent of sequence coverage by non-redundant MS/MS spectra and the molecular weight of 
the candidate protein when normalizing protein concentrations (22).  This approach can be used 
in the freely available tool BigCat (23).   
NSAF, emPAI, and the PAF are examples of normalization and analytical approaches 
that are conducted at the protein level.  An alternative approach to dealing with shared peptides 
is to first segregate peptides and proteins into peptide groups and protein groups, and conduct 
quantitative analysis at the group level instead of at the individual peptide level.  Peptide groups 
consist of all peptides that can be explained by the same set of proteins, whereas protein groups 
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are defined as all proteins that can be explained by the same set of peptide groups (Figure 1). 
Protein groups and peptide groups are already used for assembling identified proteins from 
observed peptides via parsimonious analysis (i.e. restrict identified proteins to the smallest set of 
proteins required to explain the presence of all identified peptides) (24, 25).  Instead of 
addressing shared peptides between unique proteins at the protein-level and peptide-level, group-
level analysis segregates between unique peptide groups and shared peptide groups.  All peptides 
in a given peptide group are considered to be shared between all of the proteins in each protein 
group associated with the peptide group.     
 Quantitative peptide group-
level analysis instead of protein-
level analysis assumes a high degree 
of similarity in the relative 
expression levels of different 
proteins in the same protein group.  
This is not an entirely unreasonable 
assumption since proteins in the 
same protein group presumably 
share a high degree of sequence homology and are likely in the same protein family.  Increased 
sequence homology (i.e. the number of peptides in a peptide group) confers greater likelihood of 
shared transcription factors and other regulatory mechanisms (26).  Jin et al. tested this 
assumption and found that proteins in the same protein group do, indeed, appear to be 
functionally related and experience similar changes in relative abundance when the biological 
system is perturbed (27).  They also found that the addition of shared peptides (within a given 
 
Figure 1.  A schematic of the relationship between protein 
groups and peptide groups as defined in this study.  “Shared 
Peptides” are considered to be peptides in a peptide group 
shared between two protein groups. 
 Prot1, Prot2, 
Prot3 
 Prot4, Prot5 
 PepA, PepB, 
PepC 
 PepD, PepE 
 
PepF, PepG, 
PepI, PepJ 
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protein group) did not negatively impact abundance calculations.  This observation can be 
reconciled with previous findings by noting that Usaite et al. segregated peptides based on 
whether or not they were shared or unique to the candidate protein(15).  Jin et al. took a different 
approach by segregating peptides based on whether or not they were shared between different 
sets of functionally related proteins or shared between different sets of functionally unrelated 
proteins.  Overall, their findings suggest that shared peptides within an unshared peptide group 
should not be discarded, whereas the peptides in a shared peptide group may be more 
problematic for quantitation.      
If the peptides found within a given unshared peptide group are exclusively used to 
conduct quantitative analysis, NSAF or some other normalization methods could presumably be 
applied separately for each protein in the associated protein group.   Alternatively, protein-
specific normalization could be skipped and each protein in the protein group could be treated 
equally.  There are tradeoffs to both approaches.  Normalizing each protein separately has the 
obvious advantage of factoring in differences in protein length and/or sequence coverage.  But 
testing each protein separately comes at the cost of conducting a separate statistical test for each 
individual protein whereas group-level analysis requires only a single test per protein in a group.  
The fold-change reduction in the number of statistical tests would be equal to the average 
number of proteins in each protein group tested.  Thus, type I and type II errors may be 
simultaneously reduced by protein-specific normalization but also increased due to additional 
testing vs. protein-group testing.   
Whether or not proteins are tested at the protein or protein group level has the potential to 
impact the application of multiple testing correction methods.  These methods skew results 
towards fewer false positives at the cost of more false negatives.  Independence between separate 
14 
 
tests that generate a p-value is a requirement for many multiple testing correction methods.  
Proteins in the same protein group that are normalized separately have a clear violation of 
independence, complicating the application of multiple testing corrections.  Similar problems 
arise if difference testing is restricted to the protein group-level using, all peptides from shared or 
unshared peptide groups associated with a given protein group. 
Difference testing at the peptide group-level is a third alternative.  It has the obvious 
disadvantage of reducing the overall amount of data used for a given protein‟s or protein group‟s 
testing.  But by splitting the signal between shared and unshared peptide groups, the unshared 
peptide groups provide units of peptide signal grouped for greater sequence homology.  This is 
because the proteins in a given protein group tend to be more homologous to each other than 
with randomly selected identified proteins.  And as already mentioned, greater sequence 
homology is associated with a greater likelihood of shared transcription factors, and greater 
similarity change in expression in response to stimulus (26).   
The issue of multiple testing correction is also a challenge in the field of mRNA 
microarray analysis, where thousands of genes are tested simultaneously, often on few replicates.  
Not surprisingly, LC-MS/MS proteomic analysis has borrowed a number of the data 
normalization and statistical testing techniques developed for microarray techniques (17, 28).  
One existing tool, QSpec, uses the hierarchical Bayes methodology for approximating false 
discovery rates following statistical analysis on spectral counts (29).  Another technique, the 
empirical Bayes t-test, was designed for addressing the problem of type I and type II errors 
randomly arising from multiple tests on too few replicates.  First developed by Lonnstedt and 
Speed (30), it uses Student‟s t-test with a modified t-statistic calculated using pooled variances 
empirically derived from the standard deviations observed over the entire data set.   
15 
 
A variant of the empirical Bayes t-test was made available in the “limma” package for R 
by Smyth (31, 32) and has already been employed in the label free LC-MS proteomic difference 
testing software package Corra (33).  Corra uses LC-MS precursor intensity data to conduct its 
difference testing.  In addition to using the empirical Bayes t-test to minimize false positives, 
Corra also addresses a problem not faced with spectral-count-based quantitation:  peak 
alignment.  Determining which MS1 peaks correspond to which peptide can be complicated 
because not all peptides are isolated and identified in each run.  Elution profiles can change from 
one run to the next and therefore peak area normalization or inference of an unidentified 
precursor peak‟s peptide can require complex, computationally expensive algorithms.   
Rosetta‟s “Elucidator,” a commercially available software tool, is another software 
platform designed for label free or labeled quantitation using LC-MS or LC-MALDI precursor 
intensities and peak alignment algorithms (34).  Elucidator groups MS1 precursor peaks based on 
their chromatographic parameters (retention time, m/z, inferred charge state, etc).  Following 
peak alignment (using PeakTeller) and normalization, Elucidator conducts analysis of variance 
(ANOVA) on grouped peaks in order to identify candidates of differentially abundant peptides 
for subsequent MS/MS identification.  This stands in contrast to spectral count-based label-free 
methods that group spectral counts based on identified peptides (and associated proteins).  This 
highlights a fundamentally different aspect between MS and MS/MS data.  MS data for all 
peptides are collected in profiling mode, but the specific peptides that contributed to each peak‟s 
intensity are ambiguous without MS/MS data.  MS/MS spectral count data, on the other hand, is 
only collected for some peptides, but it also doesn‟t suffer from the ambiguity of precursor peaks 
because only identified MS/MS spectra are used for spectral counting.  As such, de-noising 
steps, such as deconvolution of peak intensities of precursor peptide isotopic distributions (PIDs) 
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from their neighbors, are requirements for MS1 quantitation, but not for spectral count-based 
methods.   
Another way in which the grouping of data points for quantitation can differ between 
precursor intensity-based methods  and spectral count-based methods is the need for the exact 
same peptide (often at the same charge state) to be identified in multiple runs across cohorts.  
When precursor intensity methods are used, whether isotopic or label free methods are chosen, 
each individual peptide‟s precursor peaks are paired across runs and analyzed separately.  Label 
free, spectral count-based methods group all spectral counts for a given protein or peptide group 
together within a given cohort or technical replicate, regardless of whether the same peptides 
were found across runs.  Consequently, missing data is potentially a much larger issue when 
conducting precursor intensity-based methods because it may limit the number of peptides (and 
proteins, indirectly) that are viable candidates for a given statistical test available for precursor 
intensity analysis (i.e. Student‟s t-test requires three data points per cohort). 
QuasiTel, a tool recently developed for spectral count-based analysis by Li et al., was 
designed to address complications that can arise during quantitation of less abundant peptides 
using spectral counts (35).  As discussed above, count-based based methods can be problematic 
for low abundance proteins, partly due to the lack of continuity as counts approach zero.  Like 
precursor intensities, Poisson distributions are exponential and equal variances across the range 
of values cannot be assumed based on empirical evidence, limiting the statistical methods 
available for analysis.  Like the NSAF normalization method, which was shown to exhibit equal 
variance when the natural log of the NSAF was used (16), QuasiTel‟s developers proposed the 
use of a quasi-Poisson likelihood maximization function to be used to fit spectral count data to 
linear models that assume equal variance (e.g. a Poisson regression).  They spiked proteins at 
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different ratios to compare the performance of their quasi-likelihood model to detect 
differentially abundant proteins with the performance of classical difference tests (e.g. Fisher‟s 
exact test).  They found their new model to perform comparably to the classical tests but not 
identically.  In particular, when the spiked protein ratios were high (ratio 27) their quasi-
likelihood performed quite similarly to the other tests, but when the ratios were at the lowest  
levels tested (ratio 3), the quasi-likelihood model demonstrated a clearly superior ability to detect 
differentially abundant proteins, albeit at the cost of more false positives. As the authors pointed 
out, an advantage of their model over classical non-parametric tests is the flexibility to adapt 
spectral counts to the fitted models to include additional parameters, such as the type of 
instrument used.    
The observation of the QuasiTel authors that their model performed better at detecting 
differentially abundant proteins that were close in abundance, but at the cost of more false 
positives, is a reminder that different statistical methodologies present a different set of tradeoffs 
between sensitivity and specificity.  Which test a researcher finds appropriate depends, in part, in 
the researcher‟s goals.  If candidate proteins based on differential abundance are desired for 
subsequent analysis where the cost of false positives is not high (e.g. biomarker detection), a test 
like the QuasiTel model that yields more true positives at the expense of additional false 
positives may be the optimal choice.  On the other hand, if there is a high cost for false positives, 
a more conservative test like Fisher‟s exact test may be desired.  Such tradeoffs apply to the 
choice of precursor intensities over spectral count data for quantitation.  Based on published 
studies, if a researcher is most interested in calculating abundance ratios between cohorts, both 
spectral counts and precursor intensities can accomplish this, but precursor intensities would 
probably provide the more accurate results.  If the researcher desires to know which proteins 
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changed in abundance regardless of the fold-change, a spectral count-based approach would be 
recommended.    
The published research on LC-MS quantitation provides a vast array of methods available 
for quantitation, but these are proposed as “either/or” options from which a researcher should 
choose just one to conduct their analysis.  Some of the numerous tools available, such as Census, 
are capable of quantitative analysis using either spectral counts or precursor intensities (12).  A 
fascinating question raised by the wide variety of data types and methods available for 
quantitation is whether or not there is a method for combining the information from both 
precursor intensities and spectral counts into a single model for quantitation.   
Spectral count and precursor intensity quantitation represent two different methods of 
viewing the same underlying system.  This suggests the possible use of meta-analysis techniques 
for combining the separate quantitative statistical test results on the same protein (or peptide 
group) from separate spectral count and precursor intensity tests.  A number of different meta-
analysis techniques exist for combining the results of multiple statistical tests.  One method, the 
Winer method (36), involves the combination of t-statistics and degrees of freedom to generate a 
single new Z-statistic.  This method however, approximates the variance of the Z-statistic using 
the degrees of freedom from the underlying combined tests and suffers if the tests were 
conducted on small numbers of samples (e.g. ≤ 10).    Similarly, Stouffer‟s method generates 
new Z-statistics from the separate Z-statistics of the combined tests but it also suffers from 
reduced degrees of freedom, which is commonplace in LC-MS/MS data with few replicates (36).   
The original meta-analysis method proposed by R. A. Fisher (referred to as “Fisher‟s 
Method”) is rooted in the observation that the p-values from continuously distributed test 
statistics will have a uniform distribution under the null hypothesis for any underlying data 
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distribution (37).  Fisher‟s Method is sometimes called the Inverse Chi-squared method because 
it uses a relationship between the uniform distribution and chi-squared distribution, namely that  
-2 * log of a uniformly distributed value will follow a chi-squared distribution on 2-degrees of 
freedom.  Additionally, the sum of chi-squared distributed values will also follow a chi-squared 
distribution (37).  These observations allow for the combination of the product of multiple p-
values into a single test statistic, X
2
 that follows a chi-squared distribution with 2k degrees of 
freedom, where k is the number of separate tests (2.2):     
 
       ∑   (  )                    (   )
 
    
 
We can then generate a one-tailed p-value for X
2
 given the 2k degrees of freedom.  Fisher‟s 
Method of meta-analysis is generally considered the most powerful and widely recommended 
meta-analysis technique(37).  The application of Fisher‟s Method to LC-MS/MS quantitation is 
an intriguing possible approach to building a statistical model that incorporates both spectral 
counts and precursor intensities. 
 
Significance 
 
The goal of this study was to test the hypothesis that proteomic difference testing could 
be improved by combining spectral count and precursor intensity data into a single test.  We also 
wanted to compare the performance of the combined model to an array of classical statistical 
tests as well as the newer empirical Bayes t-test.  Our combined model consists of using Fisher‟s 
Method of combining the p-values of two of our candidate tests.  In Chapter III, we describe the 
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new combined statistical model and candidate tests in greater detail.  We also describe 
IDPQuantify, a new module of the IDPicker protein identification software suite used to generate 
the spectral count and precursor intensity data to conduct the statistical testing.  IDPQuantify 
reads protein and peptide identification results from IDPicker, a tool designed to confidently 
assemble identified proteins from peptide searches on shotgun proteomic data.  IDPicker can 
take advantage of multiple scores per peptide and decoy FDR techniques for confident peptide 
identification coupled (38).  Protein assembly with IDPicker includes bipartite analysis at the 
peptide group and protein group level for parsimonious scoring of candidate protein 
identification (24).   
IDPQuantify extends the IDPicker pipeline by providing quantitative data for the 
peptides and proteins from IDPicker‟s protein identification results.  IPDQuantify writes spectral 
count and precursor intensity data at the peptide and peptide group level (where “peptide group” 
is defined as all peptides shared by the same protein group).  Unlike precursor intensity 
quantitation tools which conduct precursor intensity analysis on peaks prior to peptide 
identification, IDPQuantify restricts precursor ion intensities to those peaks that generate an 
identified spectrum.   
IDPQuantify can also be configured to feed its quantitative output files to user-written R 
scripts for automated statistical analysis. In Chapter IV we describe our use of the 2009 
Proteome Informatics Research Group (iPRG) E. coli data set, along with IDPQuantify and R, to 
compare and contrast multiple statistical difference tests using either spectral count data or 
precursor intensity data.  These results were then compared to our combined model.  Using the 
F1-measure and ROC curves as our metrics, we show a significant improvement is possible by 
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combining both spectral count data and precursor intensity into a single statistical model 
conducted at the peptide group level. 
In this study we also introduce difference testing at the peptide group level instead of at 
the protein level as is normally done.  By grouping data (spectral counts or precursor intensities) 
at the peptide group level we are using observations made by Jin et al. that proteins in protein 
groups tend to be functionally related and also tend to change in abundance in a positively 
correlated manner (27).  Thus, we are addressing the issue of spectral counts from shared 
peptides differently than the various shared peptide normalization techniques described above.  
Unlike approaches like NSAF or emPAI, our approach does not attempt to distribute the signal 
of shared peptides between potential parent proteins or normalize that signal separately for each 
protein as long as those proteins are in the same protein group and therefore assumed to be 
functionally related and likely to change in abundance similarly.  In doing so, we lack the added 
accuracy potentially obtained by normalizing each protein‟s spectral count to the protein length, 
but we gain several important advantages.  First, by not distributing the signal of spectral counts 
from shared peptides between the potential protein parents, we add to the power of our tests by 
using more information (in the form of spectral counts) for each statistical test.   Combining 
counts at the peptide group level also helps address the problems discussed above that spectral-
count based quantitative methods tend to have when counts are low.  We also avoid 
complications associated with multiple testing corrections and the requirement for independence 
between tests.  Proteins within the same protein group that are statistically tested separately are 
clearly not independent given their shared peptide signals.  Additionally, significantly more 
statistical tests will have to be conducted if done at the protein level instead of the protein group 
level.  By quantitating at the peptide group level we are reducing the overall number of tests, and 
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thus reducing the likelihood of type I errors, while increasing the independence between tests 
which makes the results amendable to multiple testing correction procedures. 
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CHAPTER III 
 
IDPQUANTIFY AND STATISTICAL DIFFERENCE TESTING 
 
Introduction 
 
We introduce IDPQuantify, a new component of the IDPicker pipeline that generates output of 
precursor ion intensities from identified spectra at the peptide group level.  IDPQuantify 
calculates precursor ion intensities using input files generated by two third-party tools built by 
the MacCoss group, Hardklör and Bullseye (39, 40).  IDPQuantify is also capable of running 
user-written scripts in R for automated difference testing at the peptide group-level with 
precursor ion intensities and/or spectral counts  (41).   
 
Utility of IDPQuantify 
 
IDPQuantify is a new open source module written in C# for use in the IDPicker 
proteomics pipeline (38).  IDPQuantify reads idpXML files created by IDPicker, along with 
spectral source files in the .mzXML or .Raw formats, and generates output files containing 
spectral count data and precursor ion intensities for each peptide group found in each replicate.  
The output files are designed for easy extraction of peptide group-level for use in statistical 
difference testing in third party tools such the statistical package R. In addition, IDPQuantify 
produces a variety of normalized precursor intensity files (described below) that can alternatively 
be used for difference testing.   
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Users can also set up IDPQuantify to automate any number of difference tests written in 
R via the “analysis_config” text file.  Within the “analysis_config” file, the idpXML input files 
used to generate the spectral count and PPID files are then assigned to cohort 1 or cohort 2 for 
difference testing.  Users can create custom-made R scripts written to accept IDPQuantify‟s 
PPID and spectral count files and output the test results in a specified format (see Supplemental 
Materials File 4).  Which PPID and/or spectral count files are to be processed by which R script 
is defined in the “analysis_config” file.  
 
Hardklör, Bullseye, and Persistent Peptide Isotopic Distributions for Precursor Intensity 
Information Extraction  
 
To generate ms1 precursor intensity data, IDPQuantify uses input files generated by two 
third-party tools, Hardklör (39) and Bullseye (40), both developed by the Hoopman et al.. 
Hardklör reads spectral data files (.RAW, .ms1, or .mzXML) and uses a novel algorithm to 
rapidly identify peptide isotopic distributions (PIDs) within ms1 scans.  For each ms2 scan, 
Bullseye attempts to identify persistent PIDs found across sequential ms1 scans for the selected 
precursor peptide (Figure 2). 
 
Hardklör for Isotopic Deconvolution and Precursor Peak Intensity Estimation 
 
Hardklör uses a novel approach to deconvoluting neighboring isotopic distributions by 
using an efficient single-pass charge state inference algorithm.  As the Hardklör authors point 
out, efficient charge state inference is useful in quantitative applications because it allows for a 
combinatorial approach to deisotoping overlapping PIDs that can be otherwise computationally 
prohibitively expensive (39).  The number of theoretical combinations of overlapping PIDs that 
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must be considered when using the combinatorial approach grows exponentially with the number 
of charge states to be considered for the overlapping PIDs.  Hardklör‟s efficient elimination of 
charge states from consideration for a given set of PIDs can significantly reduce the computation 
costs of the combinatorial approach, making it available when less computationally expensive 
methods might otherwise be used.  Those include choosing a single PID to start the analysis with 
and iteratively subtracting computed PID signals from the remaining signal to be analyzed.  
These alternative approaches are vulnerable to the cascading effects of errors introduced early in 
the chain of analysis, which can be particularly harmful to quantitative studies.  The ability to use 
the combinatorial approach for more accurate approximation of PID peak intensities is especially 
useful when analyzing complex samples that have had limited separation, such as one dimension 
LC separation, as opposed to multidimensional separation involving strong cation exchange 
(SCX) or isoelectric focusing (IEF).   
Hardklör writes .hk files that contain summary information for each PID found in each 
MS1 scan in a given spectral data file.  The intensity of the base peak of each PID is included in 
that output.   As part of Hardklör‟s peak-picking algorithm, base peak signal is de-noised using 
the THRASH algorithm (39, 42).  The THRASH algorithm defines baseline noise in a given m/z 
window as the mode of the distribution of peaks observed at that window and subtracts that from 
the measure base peak‟s area under the curve (AUC).   
 
Bullseye for Precursor Peak Quantitation Using PPIDs 
 
Peptides eluting from the column over a long enough chromatographic window can be 
captured by multiple sequential MS1 scans.  If precursor intensities are to be used for 
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quantitation, we need to estimate the precursor peak intensities across the entire chromatographic 
window of a given peptide.  Bullseye, a companion tool built to work with Hardklör, 
accomplishes this task.  Bullseye was written for the purpose of more accurately estimating 
precursor ion m/z values than is typically done by instrument hardware/software.  A given PID 
eluting over time that is measured in multiple MS1 scans may have slightly different m/z values 
in each MS1 scan, reflecting the noise in precursor m/z values used in peptide identification.  
Bullseye assumes PIDs that appear in sequential MS1 scans with approximately the same 
monoisotopic mass all come from the same peptide.  As Hoopman et al. demonstrated, the 
average m/z of the precursor PID monoisotopic peaks observed over the entire peptide elution 
profile can yield a more accurate estimation of precursor monoisotopic m/z values than from a 
single scan alone (39).  Bullseye‟s ability to accurately estimate precursor monoisotopic m/z 
values resulted in more accurate peptide identifications even when compared to the m/z values 
provided by a high-resolution Orbitrap (39).  
Bullseye reads Hardklör‟s output files along with an ms2 spectral data file (.RAW or 
.mzXML).   For each identified MS2 spectrum, Bullseye locates ms1 persistent PIDs (PPIDs) for 
the precursor ions corresponding to each MS2 spectra.  Bullseye defines a PPID as the same PID 
in three out of four subsequent MS1 scans.  PPID intensity values consist of the summation of 
the de-noised and baselined peak AUCs of the PID‟s base peak for each ms1 scan in the PPID.  
Thus, each PPID is a Volume Under Curve (VUC) calculation of the PPID‟s base peak (Figure 
2).    Users can generate Hardklör/Bullseye files on their own or let IDPQuantify automate the  
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generation of the Hardklör and Bullseye files.  IDPQuantify‟s basic unit of quantitation at the 
peptide level is the corresponding PPID generated by Hardklör and Bullseye.  
Low intensity PIDs can result in atypical isotopic packets that make PID identification 
difficult and result in missing data points in our PPID analysis.  When an identified MS/MS 
spectrum does not have a corresponding PPID, IDPQuantify attempts to construct a PPID using 
the mass and charge of the identified peptide and the precursor triggering ms1 scan peaks.  If an 
incomplete PID is detected within a user-set retention time window (e.g. +/- 10 seconds around 
triggering ms1 scan), IDPQuantify reattempts to construct a PPID for that peptide using the 
incomplete PID as a starting point.   
It is important to note that Bullseye identifies a PPID in a given replicate only if that 
PPID was selected for MS/MS identification.  The tradeoff between this approach and other 
 
Figure 2.  Precursor intensity information extracted by IDPQuantify consists of the volume under the curve 
(VUC) of the base peak of a persistent peptide isotopic distribution.  IDPQuantify uses two third party tools 
to obtain PPIDs.  First, peptide isotopic distributions (PID) in each MS scan are deconvoluted and identified 
by Hardklör.  Next, for each MS/MS scan, Bullseye examines the triggering ion‟s PID and attempts to 
identify a corresponding persistent PID (PPID).  The sum of the areas under the curve of the PIDs base peak 
is reported by Bullseye and used by IDPQuantify. 
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methods that use peak alignment to identify unidentified precursor ions is that IDPQuantify‟s 
PPID data will include more missing data points, but also a reduced likelihood of 
misaligned/misidentified precursor peaks. 
 
Output Files Generated by IDPQuantify 
 
IDPQuantify generates a variety of output files containing spectral count and PPID data 
at the peptide and peptide group levels.  The generation and use of these files is handled by 
IDPQuantify.  The “Distinct peptides per peptide group per replicate” file contains the number 
of distinct peptides observed in each replicate in each peptide group.  The cohort-level totals and 
all-replicate-level total counts are simple summations of the replicate-level unique peptides.  The 
“Unique peptides per peptide group per cohort/run” file contains the number of unique peptides 
observed in each replicate in each peptide group and the unique peptides across each cohort and 
all replicates.   
          The “Spectral count per peptide group” file contains the number of MS/MS spectra that 
identified a peptide in a given peptide group in each replicate and across each cohort and all 
replicates.  Similarly, the “Spectral count per peptide” file simply contains the number of 
spectral counts per peptide for each replicate.  A related file is the “Num peptide hits per peptide 
group with a PPID observed” file contains the count of peptides in a peptide group that had at 
least one PPID observed in a given replicate.  If multiple spectral counts are observed for a given 
peptide in a given replicate, that peptide will add only one to the count as long as at least one of 
those spectral hits had a corresponding PPID found. 
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The “PPID intensity per peptide file” file contains the total PPID intensity per individual 
peptide per replicate.  If multiple MS/MS spectral hits are observed for a given peptide in a given 
replicate, the intensity values of observed PPIDs are summed.  If no PPID is observed but at least 
one spectral hit is seen for a peptide in a given replicate and error code of -2 is listed.  If no PPID 
is observed and no spectral hit is seen, an error code of -4 is listed.  The “Total PPID intensity 
per peptide group” file contains the total PPID intensity for a given replicate for all peptides in a 
peptide group.   
 
 
 
Figure 3: An overview of the PPID data file generation workflow utilized by IDPQuantify.  
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Statistical Difference Testing of LC-MS/MS Data 
 
The E. coli data set used for evaluating test performance is described in greater detail in 
Chapter IV.  The data set was difference tested using a variety of candidate statistical tests.  The 
tests fall under general categories of classic statistical tests, the empirical Bayes tests, and hybrid 
tests using the geometric mean of spectral count and PPID-derived p-values combined using 
Fisher‟s Method.  We refer to the use of Fisher‟s Method in this manner as the “Combined 
Model” throughout the rest of this study.     
Two methods for weighting PPID values were tried for each PPID-based test, along with 
no weighting.  PPID or spectral count-based tests also had two optional filters applied to 
eliminate low-information peptide groups from consideration.  Each candidate test was run for 
all available combinations of weighting and filtering methods (and at different filtering levels).  
See below for details on weighting and filtering methods. 
 
Classic Statistical Tests 
 
We used three spectral count-based tests: Fisher‟s exact test, the Mann-Whitney U test, 
and a normalized Mann-Whitney U test (see below).  Student‟s t-test and Welch‟s t-test were run 
using PPID data, while Fisher‟s exact test used spectral counts.  The modified Mann-Whitney U 
test was chosen in order to minimize the occurrence of tied spectral counts.  It was conducted as 
follows:  First, spectral counts were summed for each replicate.  The first replicate in cohort 1 (as 
specified in the “analysis_config” file) is chosen as a reference replicate for normalization.  Next, 
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for each peptide group tested, the spectral count for each replicate is multiplied by the 
normalization factor:  
 
                     
(                                      )
(                                          )⁄
(   ) 
 
The modified Mann-Whitney U test is run on these normalized spectral counts. We also tested 
the Mann-Whitney U test using PPID values normalized on a 0-101 scale (see “Normalization 
Approaches” below). 
 
Limma and the Empirical Bayes t-test 
 
The “Linear Models for Microarray” (Limma) package for R was designed for 
microarray data sets (43).  We used the empirical Bayes test in Limma using a variety of data 
normalization and transformations described below. Limma‟s empirical Bayes test uses a 
moderated t-statistic based on estimated sample variances derived using the entire microarray 
probe set data.  The moderated t-statistic is calculated using posterior residual standard 
deviations in place of the normally derived standard deviations, shrinking variances towards a 
pooled estimated variance.  The pooled variance, in turn, reduces the probability of under-
estimated sample variances for a given gene (or peptide group) that will result in false positives 
from artificially high t-statistics. 
 
The Combined Model:  Fisher‟s Method for Combining p-values from Spectral Count and 
PPID Data 
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The final statistical technique evaluated in this study was the generation of a single p-
value from the p-values of two separate tests using Fisher‟s Method for combining extreme 
probabilities.  Any number of p-values could be combined using this method, and given the 
number of different tests evaluated in this study using a variety of weighting and filtering 
methods, the possible combinations of p-values that could be exhaustively combined is 
enormous.  In order to explore this novel approach in a controlled manner, we limited our 
combined model to two p-values and always chose Fisher‟s exact test on spectral counts as one 
of the two inputs.  As discussed in Chapter IV, Fisher‟s exact test was chosen as our 
“benchmark” test due to its ease of implementation, robustness against missing data, and 
published track record as a high-performance statistical test for spectral count data. 
In order to derive a p-value using Fisher‟s Method, we first generate an X2 statistic from 
our two (or more) p-values: 
 
      ∑  (  )                    (   )
 
   
 
 
The X
2 statistic follows a χ2distribution with 2k degrees of freedom, where k is the number of 
combined p-values.  We can then generate a one-tailed p-value for X
2
 given the 2k degrees of 
freedom using a built-function in R.   
For each candidate test, its p-value (for a given peptide group) was paired with the p-
value generated by Fisher‟s exact test.  For candidate tests conducted on spectral count data, this 
resulted in two p-values based on spectral counts being combined using Fisher‟s Method, which 
raises an important caveat in the application of Fisher‟s Method in this context: Fisher‟s Method 
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assumes that the combined p-values are independent of each other.  This assumption is clearly 
invalid when both p-values are derived from the same set of spectral counts using different 
statistical tests.  This assumption is also violated, though to a lesser extent, when combining p-
values from PPIDs and p-values from spectral counts if the PPIDs are generated only from 
identified spectra (e.g. PPIDs generated using Hardklör/Bullseye).   
If precursor intensity values were derived independently of spectral counts (as is the case 
for many precursor intensity-based quantitation approaches), the degree to which the two data 
types would be independent is an intriguing question.  For instance, more intense precursors are 
correlated with higher probability of peptide identification from MS/MS spectra.  To partially 
address the question of independence between spectral count and precursor intensity data, we 
explored the differences in performance biases between the PPID and spectral count-based 
statistical tests evaluated in this study in Chapter IV. 
 
Multiple Testing Correction 
 
Due to the large number of tests conducted on each set of replicates, multiple testing 
correction is needed to minimize false positives.   In this study, we applied the Benjamini-
Hochberg correction for all statistical tests when using the iPRG E. coli training data set.  
Adjusted p-values of 0.05 were treated as significant (41).  The Benjamini-Hochberg correction 
is designed to maximize the per-comparison error rate (PCER) rather than at controlling the 
family-wise error rate (FWER).  Controlling for the PCER instead of the FWER makes this 
procedure appropriate for this study because we are applying the same procedure to a variety of 
different statistical tests and cannot select the optimal test to control each.   
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The Benjamini-Hochberg correction is an FDR controlling procedure that relaxes the 
Bonferroni procedure iteratively by setting the following constraint: 
 
For hypothesis tests 1…m, order all the respective p-values from smallest to largest.  
Find the largest p-value that satisfies the following condition (3.3): 
 
 ( )  (  ⁄ ) 
         (   ) 
 
Where    is the desired FDR rate.  Once the condition is satisfied, reject the null-
hypothesis for 1…i.  
 
This method was shown by Benjamini and Hochberg to grow in power as the number of tests 
increased.  This was also the case as the number of null hypotheses to be discarded increases 
(44).  These qualities make the Benjamini-Hochberg procedure useful for a data set with a 
potentially large number of proteins tested (or peptide groups tested) that should truly have the 
null hypothesis rejected.  As is discussed in Chapter IV, the data set “answer key” generated for 
use in this study contains ~10% (115) peptide groups for which the null hypothesis can be truly 
rejected, so we are not to be concerned about imposing this procedure with too few truly 
rejectable null hypotheses.  
As discussed in Chapter II, we are conducting our difference testing at the peptide group-
level instead of the protein level, which impacts the use of the Benjamini-Hochberg procedure in 
multiple ways.  First, we are increasing the degree of independence between p-values that is 
clearly not upheld when conducting difference testing at the protein-level using the same 
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underlying quantitative data (e.g. spectral counts) that is renormalized for each protein.  
Independence between tests is a requirement of the Benjamini-Hochberg procedure in its attempt 
to control for the PCER instead of the FWER.  A second point regarding the reduction in the 
number of tests conducted is that the Benjamini-Hochberg procedure‟s FDR controlling power 
increases with the number of tests conducted (44),  so the benefit of reducing the number of tests 
is somewhat negated when using the Benjamini-Hochberg procedure to control the FDR.     
 
Missing/Observed PPID Weighting 
 
Not all identified spectra are matched to a PPID, resulting in errors that may arise from 
missing data.   In order to maximize the potential value of Bayesian estimated variance,  we 
investigated the use of weighting peptides based on the number of observed PPIDs or missing 
PPIDs for each peptide within a given peptide group.   
 For each 
peptide group in a 
replicate, the 
reported intensity 
consists of the sum 
of the PPIDs for each individual peptide in the peptide group.  The first optional filter we tested 
involved the weighting of PPID intensities for each peptide based on the number of missing or 
observed PPIDs for each individual peptide seen across all replicates.  First, we counted the 
number of replicates that included a PPID for that peptide vs. the number of replicates with no 
PPID for that given peptide.  If a PPID is observed for a given peptide/replicate pair we assign a 
Table 1.  The contingency table used to calculate the probabilities of observing the 
number of matched and unmatched PPIDs across all replicates.  Numbers in table 
assume five replicates per cohort and 32,174 out of 127,500 peptide/replicate pairs 
have at least one PPID. 
 This peptide All other peptides Total 
Matched PPIDs 2 32,174-2 = 32,172 32,174 
Unmatched PPIDs 8 95,326-8= 95,318 95,326 
Total 10 127,490 127,500 
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+1 to the “matched” count and assign a +1 to the “unmatched” count if no PPID is seen.  Using 
these “matched” and “unmatched” counts across all replicates, we then calculated the 
hypergeometric distribution of PPID observations across all replicates for a given peptide (e.g. 0-
10 PPIDs assuming 5 replicates per cohort) (Table 1).  Next, for each peptide, IPDQuantify 
computes the p-value associated with observing fewer PPIDs across all replicates based on the 
hypergeometric distribution defined above.  For instance, if a given peptide has three PPIDs 
observed across all 10 replicates, we calculate its p-value by summing the probabilities in the  
hypergeometric distribution for observing 0, 1, and 2 replicates (Table 2).  
These p-values are then used to 
weight the contribution of each peptide 
group.  Thus, when a given peptide group‟s 
total PPID intensity is calculated for a 
given replicate by summing the PPIDs of 
each of the individual peptide PPIDs, the 
peptides with only one or two PPIDs 
observed across all replicates will 
contribute less than peptides with six or 7 
observed PPIDs.  This results in stronger weighting of those peptides for which we have 
observed the most evidence. 
We also employed a similar filter using missing PPIDs per peptide.  In this case, we 
counted the number of peptides that have at least one spectral count (in any charged state) that 
could not be matched to a PPID.  This represents an instance where Bullseye was unable to find 
a PPID for a given identified peptide in a given replicate.  The total number of “matched” and 
Table 2.  The probabilities and corresponding p-values 
from the hypergeometric distribution of  32,174 
“matched” and 95,326 “unmatched” PPIDs 
Matched PPIDs probability p-value 
0 0.105372895 0.000 
1 0.265922106 0.105 
2 0.301978191 0.371 
3 0.203205768 0.673 
4 0.089732319 0.876 
5 0.0271699 0.966 
6 0.005712784 0.993 
7 0.000823633 0.999 
8 7.79242E-05 1.000 
9 4.36868E-06 1.000 
10 1.10211E-07 1.000 
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“unmatched” PPIDs across all peptides and all replicates are calculated as above.  Using these 
“unmatched” and “matched” counts we calculate the hypergeometric distribution of unmatched 
PPID observations for a given peptide (across all replicates) and subsequent p-values for the 
possibility of observing fewer missing but expected PPIDs across all replicates.  We then use (1 - 
p-value) to weight the contribution of each peptide‟s PPID when calculating the peptide group 
PPID.   
 
PPID Count/Spectral Count Filtering 
 
A second category of filter evaluated in this paper involved simply removing from 
consideration those peptide groups that had less than the threshold value of PPIDs (or spectral 
counts) observed across all replicates.  The “minimum PPID per peptide group” filter counts the 
total number of PPIDs observed across all replicates (in both cohorts) for a given peptide group 
and removes that peptide group from further consideration if the total number PPIDs is than the 
minimum threshold.  This filter is applied before subsequent normalization steps (e.g. percentile 
normalization, see below), thus possibly altering the distribution of normalized values.  The 
second filter we tried is a “minimum PPID in at least one cohort per peptide group” filter.  This 
filter counts the total number of PPIDs observed in both cohorts for a given peptide group.  If 
neither one of the cohorts meets the minimum PPID threshold, that peptide group is removed 
from further consideration.  The minimum PPID filters used in this study were 0, 5, 10, 15, 20, 
and 25 for both filters.  For statistical tests based on spectral counts, we employed peptide group 
spectral count filters analogous to the PPID filters described above. 
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Normalization Approaches  
 
The distribution of PPID intensities within a given replicate closely matches the typical 
exponential decay distribution of spectral intensity data.  While the distributions of different 
replicates tend to be similar, the raw intensity values can vary significantly from replicate to 
replicate, necessitating the need for normalization. Following peptide group-level PPID 
calculations, and optional missing PPID weighting and/or filtering, two different normalization 
approaches were tested:  replicate-level percentile normalization, and maximum value per 
replicate normalization. 
 When percentile normalization was used, each replicate‟s peptide group-level intensities 
are percentile normalized separately.  First, non-zero PPIDs are separated from the zero-values.  
Each non-zero PPID is ranked highest to lowest and assigned a percentile value, with 0 being the 
most intense and 99 being the least non-zero intensity.  Next, the peptide groups which have 
PPID intensities of 0 but spectral counts greater than 0 are assigned a value of 100.  Finally, 
peptide groups where no PPIDs were observed and none were expected are assigned a value of 
101.  This has the result of creating a flat, uniform distribution of non-zero PPID values for 
subsequent analysis. For maximum value normalization, we simply divided each peptide group 
PPID by the maximum PPID value in its replicate.  This results in a distribution between 0 and 1 
for subsequent analysis that retains its exponential decay distribution. 
 
PPID Data Transformations 
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Following normalization and/or minimum PPID filtering, two different transformations 
were tested:  the Tukey-Freeman arcsine transformation (45) and a log transformation. The 
Tukey-Freeman arcsine transformation is simply the arcsine of the square root of data 
normalized from 0-1, requiring division by 101 for percentile normalized PPID data.  For 
uniformly distributed data, the Tukey-Freeman transformation results in a roughly Gaussian 
distribution with values between 0 and  /2, centered around  /4.  When the arcsine is performed 
on exponential decay distributions (i.e. when replicates have been normalized by the maximum 
PPID value/replicate), we observe a modest shifting and broadening of the distribution away 
from the extremely low values. The second data transformation optionally tested was the log 
transformation, which has the effect of converting an exponential decay to an approximation of a 
normal distribution.  PPIDs with a value of 0 are assigned a post-log transformed value of 0.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
40 
 
CHAPTER IV 
 
IPRG E. COLI TRAINING SET 
 
Introduction 
 
In order to evaluate and compare the performance of the candidate statistical tests and our 
combined model, we used a pair of LC-MS/MS data sets consisting of two E. coli proteomes, 
each with a different segment of their proteomes removed to create sets of differentially 
abundant proteins.  The data set, the iPRG2009 Study data set, was generated by the Proteome 
Informatics Research Group iPRG, a part of the Proteomics Standards Research Group (sPRG) 
under the Association of Biomolecular Research Facilities (ABRF).  It was designed to provide 
researchers with LC-MS/MS data known to contain a significant number of differentially 
abundant proteins that can be separately verified, yielding an “answer key” for use in difference 
testing method evaluation. 
 
Materials and Methods 
 
Experimental Data Sources 
 
This data set includes two samples of LC-MS/MS data derived from E. coli lysates 
(labeled “Red” and “Yellow”), with five technical replicates for each sample.  In addition, the 
Red/Yellow samples both had complementary “Blue” and “Green” answer key samples 
consisting of three LC-MS/MS technical replicates (Figure 4).  The “Red” and “Yellow” 
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replicates were derived from the same E. coli lysate sample run on two halves of one gel with a 
single region excised from each half (The “Blue” and “Green” proteomic data sets).  The Red, 
Yellow, Blue, and Green gels were all analyzed on an LTQ-Orbitrap, and the resulting data sets 
are freely available at proteomecommons.org. 
 
  
 
source:  http://www.abrf.org/ResearchGroups/ProteomicsInformaticsResearchGroup/Studies/iPRG2009_presentation.pdf 
Figure 4: The “Red/Yellow” iPRG 2009 LC-MS/MS data set with “Blue/Green” LC-MS/MS answer keys.  
Differential proteomic analysis of the Blue/Green samples yields “true positives” of peptides up or down.  
 
 
Peptide Identification 
 
Raw spectral files were converted to the mzML format (46, 47) using msConvert (48).  Searches 
were conducted on the 20080728-Sprot-ECOLI-BSA-Cntms-reverse.fasta protein database, which 
contained forward and reverse sequences for FDR estimations.  Searches were configured to allow tryptic 
and semitryptic peptides and a static mass shift of 57.0125 Da for alkylated cysteines.  Optional allowable 
modifications were oxidation of methionine (+15.996 Da), N-terminal acetylation (+42.013 Da),   N-
terminal pyroglutamate formation (−17.0265 Da).  Search configuration parameters are shown in 
Supplemental Materials File 1.  Peptides were filtered at a 5% FDR using IDPicker. 
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Results and Discussion 
 
LC-MS/MS Data Set Summary Statistics 
 
The iPRG “Red/Yellow” E. coli spectral files were first searched for peptides using MyriMatch 
(versions 1.3.2) (49) followed by peptide group and protein group assembly using IDPicker (version 
2.6.129).  Each cohort consisted of five technical replicates.  A summary of the search results at the 
peptide, peptide-group, and protein-group-level of spectral counts and PPID measurements for the iPRG 
E. coli data sets are shown using in Table 3.   
Peptide hits were determined using MyriMatch.   Measured PPIDs and missing PPIDs were 
roughly equal between the two cohorts.  The “Protein Groups/Peptide groups” ratio was 1.1, indicating 
that the only ~10% of peptide groups were shared between two or more protein groups.   Bullseye (40) 
was able to find a PPID for 74% of identified spectra.   
 
                                                
Table 3:  MS Search Summary for E. coli Red/Yellow data set.  The cohort labels are:  R=Red, Y=Yellow  
 
 
“Blue/Green” Answer Key  
 
The iPRG E. coli “Blue/Green” data set was used as the answer key for which peptides 
were differentially present in the “Red/Yellow” samples.  Peptide groups found to be 
differentially present in “Blue/Green” samples are also assumed to be differentially present in the 
 Protein 
groups 
Unique 
peptides 
Peptide 
groups 
Spectral 
count  
PPID 
measured 
Missing 
PPID 
Protein 
database 
E. coli 
R/Y 
1,403 9,124 1,275 43,687 
(21,987R / 
21,700 Y) 
32,174 
 (16,399 R / 
15,737 Y) 
11,551  
(5,588 R / 
5,963 Y) 
20080728-
Sprot-ECOLI-
BSA-Cntms-
reverse.fasta 
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“Red/Yellow” samples.  As above, peptides were searched for using MyriMatch (v. 1.3.2) using 
the same configuration as described above for the “Red/Yellow” search, followed by peptide 
group and protein group assembly using IDPicker (v 2.6.129).  Summary results are shown in 
Table 4.   
 
 
 
 
 
 
 
Table 4.  MS Search Summary for E. coli Blue/Green data set.  The cohort labels are:  B=Blue, G=Green.  
 
The “Blue/Green” data set had significantly fewer peptides, proteins, and spectral hits 
compared to its “Red/Yellow” counterpart.  This was expected because of the fewer technical 
replicates per cohort (3 vs. 5) and the fact that the excised gel regions used to generate this data 
contained protein mixtures with lower diversity than the remaining Red/Yellow gels (See figure 
4). 
 
 
“Blue/Green” Answer Key Creation 
 
Following peptide identification and peptide/protein group assembling, the answer key 
needed to be generated from the data sets.   The “Blue” and “Green” data sets each consisted of 
different, but overlapping, segments of the E. coli proteome.  A given protein found in the Blue 
or Green gel bands is presumably up or down in the Red and Yellow gel bands unless the same 
amount of protein is removed from both the Red and Yellow bands.  As such, we defined our 
answer key as those proteins found to be differentially abundant between the Blue and Green gel 
 Protein 
groups 
Unique 
peptides 
Peptide 
groups 
Spectral 
count  
Protein 
database 
E. coli 
B/G 
492 3,870 522 14,740 
(7,374 B / 
7,366 G) 
20080728-
Sprot-ECOLI-
BSA-Cntms-
reverse.fasta 
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bands using an established, safe difference test.  We chose to use spectral counts for Blue/Green 
difference testing.  Spectral count-based methods tend to be better at determining which proteins 
changed in abundance than precursor intensity-based tests (see Chapter II), and our precursor 
intensities consist of a novel, untested metric (i.e. PPID intensity values from Bullseye for 
identified spectra only).  With three replicates per cohort, the “Blue/Green” data set is potentially 
a candidate for non-parametric analogues to Student‟s t-test, such as the Mann-Whitney U test.  
But three replicates are the minimum allowable for such tests, making such a choice somewhat 
less sensitive.   Fisher‟s exact test, on the other hand, combines the data from all replicates for 
each cohort, making it a safer choice when a few replicates are available.   
After selecting the difference test to populate our answer key, we needed to determine 
whether or not multiple testing corrections were needed when defining the final set of “true 
positive” differentially present proteins.  In this comparative study, protein quantitation is done 
at the peptide group level (See Chapter III). 522 peptide groups were tested on the “Blue/Green” 
data across three replicates per cohort.  This is clearly a case of many tests on few replicates, 
necessitating proactive FDR control.  On the other hand, the Blue and Green gel bands were 
excised at different locations in the “Red/Yellow” gels, so we should expect a large of number 
differentially present peptide groups and we may risk biasing the measured performance of the 
various statistical tests run on the “Red/Yellow” training data in favor of more conservative tests 
if we erroneously retain the null hypothesis for too many truly differentially present peptide 
groups in the “answer key.”   
Running Fisher‟s exact test without multiple testing correction (for a significance level of 
p=0.05), results in the identification of 170 out of the 522 peptide groups as significantly 
different.  When the Benjamini-Hochberg correction is used, we lose approximately a third of the 
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peptide groups deemed significantly different. However, in spite of this correction, we have a list 
of 115 “true positives,” i.e. fewer than 10% of the 1,275 peptide groups found in the 
“Red/Yellow” data set compared to 13% without correction.  Because of the small number of 
replicates in our Blue/Green data sets, we chose the more conservative approach of using 
Benjamini-Hochberg correction for the answer key generation.  In addition, we observed that 
many of the peptide groups removed by the Benjamini-Hochberg correction were among the 
least abundant of the pre-corrected set of “true positives” (TPs).  Additionally, the well-
established difficulties of spectral count-based tests on low abundance proteins (See Chapter II) 
suggests that these less abundant peptide groups are more likely to be false positives.  All peptide 
groups in the Red/Yellow data set identified by IDPicker that were not in the set of “true 
positives” were assigned as “true negatives” in the answer key.   
   
Benchmark Test vs. Classic Statistical Test 
 
Using the “Blue/Green” answer key to evaluate statistical test performances and the 
“Red/Yellow” E. coli data as our data set, we compared Fisher‟s exact test on spectral counts to 
the following classical difference tests using either spectral counts or PPIDs:  Student‟s t-test on 
PPIDs (with and without log transformation), Welch‟s t-test on PPIDs (with and without log 
transformation, the Mann-Whitney U test on spectral counts (modified and unmodified), and the 
Mann-Whitney U test on PPIDs (See Chapter III for details on candidate tests).  Fisher‟s exact 
test was chosen as our benchmark due to its robustness in the face of noise/missing data and 
because it has already been evaluated and deemed effective for LC-MS/MS difference testing 
(50).   But it should also have an inherent advantage over the other selected tests because we 
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used Fisher‟s exact test to define the “answer key,” and it will therefore share the same 
hypothesis testing biases (e.g. the same family-wise error rate).  Because our multiple testing 
correction procedure, the Benjamini-Hochberg correction (44), does not attempt to control for 
the family-wise error rate (FWER) but instead focuses on the per-comparison error rate (PCER), 
this may also give our benchmark test an advantage over the candidate tests if a larger amount of  
the error for our benchmark test will arise from the PCER compared to our candidate tests. 
Due to the large number of tests conducted over the 10 replicates (1,275 peptide group 
tests), we started off using the Benjamini-Hochberg correction to reduce false positives.  Due to 
a significant loss in sensitivity by both the Mann-Whitney U test and the modified Mann-
Whitney U tests, when used in conjunction with the Benjamini-Hochberg correction, multiple 
 
                                                                       F1-Measure 
Figure 5.  The F1-measures for the classical difference tests vs. the Benchmark test on the Red/Yellow data 
sets.  Results for Mann Whitney U tests did not include the Benjamini-Hochberg correction.  No 
PPID/Spectral Count filtering or weighting methods were used for the results shown.    
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testing correction was not applied for those tests in future analyses (data not shown).  This is not 
unexpected based on sharply reduced statistical power than the Mann Whitney U test suffers as 
the number of replicates falls below 10 (51).   
 
 
The ROC curves and F1-measure for each classical test were initially calculated using the 
answer key without any PPID/Spectral count filtering or weighting (see Chapter III).  Results are 
shown in Figures 5 and 6.  The ROC curve of Fisher‟s exact test clearly outperformed all other 
tests in terms of accuracy.  The PPID-based tests (Student‟s t-test and Welch‟s t-test) showed the 
lowest accuracy, but the highest potential sensitivity if more FPs are to be tolerated.  The F1-
 
Figure 6.  The ROC curves for the classical difference tests vs. the Benchmark test on the Red/Yellow data 
sets.  Results for Mann Whitney U tests did not include the Benjamini-Hochberg correction.  No 
PPID/Spectral Count filtering or weighting methods were used for the results shown.  Our benchmark test, 
Fisher‟s exact test (Black), showed the greatest specificity but reduced sensitivity if higher false discovery 
rates were accepted. 
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measure, which equally balances the value of a test‟s precision and recall, showed a clear 
advantage to using Fisher‟s exact test on spectral counts based compared to the other tests.  
Next, we examined how PPID and spectral count filtering and weighting impacted the 
performance of these tests.  Each test was run separately using a “minimum PPID/Spectral Count 
in at least one cohort” and a “minimum PPID/Spectral Count across all cohorts” filter.  Filter 
values of 5, 10, 15, 20, and 25 were used for both filters applied.  F1-measures and AUC values 
are available in the Supplemental Materials Files 3 and 4.  A PPID or spectral count filter of 5 
slightly improved AUC values, but filter cutoffs above 5 did not help and began to hurt 
performance as the cutoff was increased.  Similarly, F1-measures improved with “minimum 
PPID/Spectral Count in at least one cohort” filter thresholds set at 5 or 10 PPID/Spectral counts 
before showing a negative impact with higher thresholds.   The “minimum PPID/Spectral Count 
across all cohorts” filter did not appear to help for these tests.  For the tests run on PPIDs, neither 
weighting method tried (“observed PPID” or “missing PPID” weighting) appeared to have 
consistently positive or negative impact. 
 
Benchmark Test vs. Empirical Bayes t-test 
 
Next, Fisher‟s exact test (on spectral counts) was used as a benchmark for comparing 
different empirical Bayes t-test methodologies.   The empirical Bayes t-test was run using either 
PPIDs or spectral counts (See Chapter III).  Results for the un-weighted/unfiltered tests are 
shown in Figures 7 and 8. 
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                                                                  F1-Measure 
Figure 7.  The F1-measures for the empirical Bayes t-tests vs. the Benchmark test (Fisher‟s exact test on 
spectral counts) on the Red/Yellow data sets.   
 
Fisher‟s exact test outperformed the empirical Bayes t-tests when either F1-measures or 
ROC analysis was used.  As with the classical test comparisons, the ROC plots showed a much 
higher accuracy for the benchmark test, but a greater potential sensitivity amongst the empirical 
Bayes t-tests if more false positives are to be tolerated.  The top performing tests based on the F1-
measure were: a) the empirical Bayes t-test using un-normalized spectral counts and b) the 
empirical Bayes t-test on PPIDs with percentile normalization and the empirical Bayes t-test on 
PPIDs with the arcsine(sqrt) transformation in addition to percentile normalization.  When 
spectral count/PPID filtering was applied, only the minimum PPID/spectral count filtering 
appeared to have any sort of consistent positive impact, with a mild improvement when the 
“minimum PPID/Spectral Count in at least one cohort” filter is set to 5 or 10, and otherwise the 
impact was detrimental to performance (See AUC/F1-Measure tables in Supplemental Materials 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
empirical Bayes PPID + max value norm + log transformation
empirical Bayes PPID + max value norm
empirical Bayes PPID + (%+arcsin) norm
empirical Bayes PPID + % norm
empirical Bayes PPID + log norm
empirical Bayes PPID no norm
Fisher's exact test
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Files 3 and 4).  Neither PPID weighting methods showed a consistent positive or negative 
impact. 
 
 
 
Benchmark Test vs. Combined Model 
 
 Our combined model that incorporates information from both precursor intensity and 
spectral count information for improved quantitation consists of using Fisher‟s Method to 
combine the p-values of a single test evaluated in this study (classical or empirical Bayes) with 
 
Figure 8.  The ROC curves for the empirical Bayes t-test vs. the Benchmark test (Fisher‟s exact test on 
spectral counts) on the Red/Yellow data sets.  All empirical Bayes tests were run using PPIDs, except the test 
coded in purple which was run using un-normalized spectral counts.   Our benchmark test, Fisher‟s exact test 
(Black), showed the greatest specificity but reduced sensitivity if higher false discovery rates were accepted. 
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the p-values of the benchmark test (Fisher‟s exact test on spectral counts at the peptide group 
level).  This model was applied for all tests evaluated in this study. While the intent of this study 
was to combine precursor and spectral count data into a single statistical test for LC-MS/MS 
quantitation, we included candidate tests using spectral counts so PPID/Spectral Count and 
Spectral Count/Spectral Count combinations were examined.  The combination of two tests on 
spectral counts is a reminder that independence is being violated to some extent in the 
application of Fisher‟s Method, although, as will be discussed below, the PPID and spectral 
count-based approaches appear to select for overlapping, but distinct sets of peptides.  
 
Benchmark Test vs. Combined Model Using Classical Tests 
 
The combined model on the classical tests showed a sharp rise in the F1-measures that 
virtually matched that of the benchmark test in all cases (Figure 9).  The ROC curves clustered 
around the benchmark test‟s ROC (Figure 10).  The Student‟s t-test and Welch‟s t-test compared 
best to the benchmark test, both showing a higher sensitivity than the benchmark if more false 
positives are accepted.  Table 5 shows the F1-Measures of the candidate tests before and after the 
application of the combined model.  In general, the worst performing tests showed the largest 
improvement.  For example, the Welch‟s t-test on PPIDs, which performed the worst alone, showed the 
greatest rise after the combined model was applied (47%). 
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Table 5.  Percentage Change in F1-Measures of Classical Candidate Tests Following Application of 
Combined Model 
Candidate Test Candidate Test Alone 
Combined Model (Candidate 
Test + Benchmark) % Change 
Student's t-test on PPIDs 0.60 0.71 18% 
Student's t-test log transformation on 
PPIDs 0.55 0.70 27% 
Welch's t-test on PPIDs 0.49 0.72 47% 
Welch's t-test log transformation on 
PPIDs 0.55 0.70 27% 
Mann Whitney U test on Spectral 
Counts 0.58 0.70 21% 
Modified Mann Whitney U test on 
Spectral Counts 0.64 0.71 11% 
Mann Whitney U test on PPIDs 0.58 0.72 24% 
                                                                  F1-Measure 
Figure 9.  The F1-measures for the combined model using the classical tests combined with the Benchmark 
test (Fisher‟s exact test on spectral counts) on the Red/Yellow data sets.   
 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
Mann Whitney U test on PPID
Modified Mann Whitney U test on Spectral Counts
Mann Whitney U test on Spectral Counts
Welch's t-test log transformation
Welch's t-test log transformation
Student's t-test log transformation
Student's t-test
Fisher's exact test
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Benchmark Test vs. Combined Model Using Empirical Bayes t-tests 
 
The combined model on the empirical Bayes t-tests showed a sharp rise in the F1-
measures that matched or surpassed that of the benchmark test in all but two cases (Figure 11). 
The ROC curves clustered around the benchmark test‟s ROC (Figure 12).  Similar to the 
combined model on the classical test, the combined model on the empirical Bayes ROC curves 
indicated a mild tradeoff of more false positives for fewer false negatives relative to the 
benchmark test.  Table 6 shows the percentage change in F1-Measures following application of 
the combined model for example tests (no weighting or filtering applied).  Like the classical 
 
Figure 10.  The ROC Curves for the classical difference test methods after combination with benchmark test 
(Fisher‟s exact test with spectral counts).  The ROC curve for our benchmark test did not have the combined 
model applied.   Our benchmark test, Fisher‟s exact test (Black), showed the greatest specificity but reduced 
sensitivity if higher false discovery rates were accepted. 
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tests, the empirical Bayes t-tests with the worst initial F1-Measures (the tests employing “max 
value normalization”) showed the greatest percentage increase. 
 
 
 
Table 6.  Percentage Change in F1-Measures of Empirical Bayes t-test Candidate Tests Following 
Application of Combined Model 
Candidate Test 
Candidate 
Test Alone 
Combined Model (Candidate 
Test + Benchmark) % Change 
empirical Bayes on PPIDs 0.63 0.73 16% 
empirical Bayes on PPIDs + log normalization 0.58 0.7 21% 
empirical Bayes on PPIDs + percentile normalization 0.66 0.74 12% 
empirical Bayes on PPIDs + percentile+arcsine(sqrt) 
normalization 0.65 0.72 11% 
empirical Bayes on PPIDs + max value normalization 0.49 0.61 24% 
empirical Bayes on PPIDs + max value normalization 
+ log transformation 0.56 0.73 30% 
empirical Bayes on PPIDs + max value 
normalization+arcsine(sqrt) 0.5 0.6 20% 
empirical Bayes on Spectral Counts 0.67 0.73 9% 
 
 
 
 
                                                      F1-Measure 
Figure 11.  The F1-measures for the empirical Bayes difference test methods after combination with Fisher‟s 
exact test 
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Venn Analysis 
 
The improved performance for virtually every test using Fisher‟s Method to combine 
Fisher‟s exact test with the candidate test can be partially explained by examining the overlap 
and differences in the difference test‟s ability to find true positives (TP), false positives (FP), 
false negatives (FN), and true negatives (TN).  In order to analyze the similarity in performance 
and discriminatory bias amongst the statistical tests examined in this study, Venn charts were 
created comparing the sets of TP, FP results for the benchmark test (Fisher‟s exact test on 
 
Figure 12.  The AUC-measures for the combined model using the empirical Bayes t-test combined with the 
benchmark test (Fisher‟s exact test on spectral counts) test methods.  The ROC curve for our benchmark test 
did not have the combined model applied.  The benchmark test (Black) showed the specificity, with reduced 
sensitivity if higher false discovery rates were allowed. 
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spectral counts).   The FN and TN plots can be inferred from the TP and FP plots and are not 
shown. 
 
Venn Analysis for Classical tests vs. Benchmark Test  
 
Venn charts of TPs and FPs generated by the classical tests vs. the benchmark test are 
shown in Figure 13.  The Student‟s t-test had a strong overlap with the benchmark test, with each 
test sharing the same group of 60 TPs and only 11 and 9 unique TPs found by each test, 
respectively.  The Welch‟s t-test, which performed the worst amongst the classical tests 
evaluated, found only 46 TPs overall (vs. 69 for the benchmark) and only 6 of those TPs were 
not also found by the benchmark test.   
 
The Mann Whitney U tests (on spectral counts or PPIDs) found significantly more TPs 
than the benchmark test, including virtually all of the same TPs found by the benchmark test.  
 
                                      True Positives                False Positives 
Figure 13.  Venn charts of the true positives and false positives generated by the classical candidate tests vs. 
the benchmark test.  A total of 115 true positives existed in the blue/green “answer key”.  The Mann Whitney 
U tests had no Benjamini-Hochberg procedure applied. 
0 50 100
Mann Whitney U test (spectral
counts) vs. Benchmark
Mann Whitney U test (% norm
PPID) vs. Benchmark
Student's t-test (PPID) vs.
Benchmark
Welch's t-test (PPID) vs.
Benchmark
0 50 100
Candidate
Test
Both Tests
Benchmark
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The high sensitivity of the Mann Whitney U tests was not unexpected.  Likewise, the Mann 
Whitney U tests showed 10-fold (or greater) more FPs compared to the benchmark test.  This 
was not unexpected as the Mann Whitney U tests were the only candidate tests to have the 
Benjamini-Hochberg correction removed in this study, highlighting the tradeoff between 
sensitivity and accuracy that multiple testing corrections offer.   
The Student‟s t-test and Welch‟s t-test had ~6 and 3-fold more FPs respectively than the 
benchmark test (43 vs. 7 and 19 vs. 7, respectively).  Interestingly, while the benchmark test had 
a very small number of false positives (7), the Student‟s t-test and Welch‟s t-test shared only 4 
and 3 FPs, respectively, of the 7 FPs found by the benchmark test.  
 
Venn Charts for Empirical Bayes t-tests vs. Benchmark Test  
 
Example Venn charts of TPs and FPs generated by the empirical Bayes t-tests vs. the 
benchmark test are shown in Figure 14.  Overall, the empirical Bayes t-test appeared to find most 
or all of the same TPs found by the benchmark test with 12-18 TPs not found by the benchmark 
test.  Using the log transformation on PPID data worsened performance relative to un-normalized 
PPIDs, percentile normalized PPIDs, or even un-normalized spectral counts.  This is in keeping 
with the relative performance of the classical tests, where the log transformation of PPID data for 
both the Student‟s t-test and Welch‟s t-test underperformed tests conducted on the raw PPID data 
(based on F1-measure and ROC analysis).  The negative impact of the log transformation on 
these candidate tests suggest the need for variance analysis on PPID data grouped at the peptide 
group level in order to explore the distribution and the most appropriate data normalization and 
transformations.  The lower sensitivity of the empirical Bayes t-test on log transformed PPIDs 
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was coupled with an overall lower level of FPs relative to the other empirical Bayes t-tests, 
similar to the Welch‟s t-test.   
 
  
It is worth noting that the empirical Bayes t-test on spectral counts appeared to perform 
much more similarly to its PPID counter-parts than the benchmark test on spectral counts.  
Likewise, the Mann Whitney U test on spectral counts performed much more similarly to the 
Mann Whitney U test on PPIDs than to Fisher‟s exact test on spectral counts.  This suggests that 
the degree of independence between the performances of different candidate tests depend both 
on difference in the data type chosen (e.g. spectral counts vs. PPIDs) and also the inherent 
systematic biases specific to each test.   
 
Venn Charts for Combined Model vs. Benchmark Test  
 
  
                                     True Positives               False Positives 
Figure 14.  Venn charts of the true positives and false positives generated by the empirical Bayes candidate 
tests vs. the benchmark test.  A total of 115 true positives existed in the blue/green “answer key” 
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Next, Venn charts of TPs and FPs generated by the combined model vs. the benchmark 
were analyzed.  Figure 15 shows the impact of using the combined model with each of the 
example classical tests.  In every case, both the TPs and FPs generated by the combined model 
showed a strong shift towards the TPs and FPs of the benchmark test.  The combined models on 
the Mann Whitney U tests (with either spectral or PPIDs) showed a mild drop in TPs coupled 
with an even sharper drop in FPs relative to the Mann Whitney U tests alone.  The combined 
model using Student‟s t-test on PPIDs showed a slight rise in TPs and a significant drop in FPs.  
Welch‟s t-test, which had fewer TPs than the benchmark test, showed the greatest increase in 
TPs (46 to 68) while also seeing a drop in FPs when used in the combined model from 19 to 6 
FPs.  This was the only instance where the combined model had fewer FPs than the benchmark 
test alone (which had 7 FPs).   
 
 
 
                                                                 True Positives                               False Positives 
Figure 15.   Venn charts of true positives and false positives.  For both true positives and false positives, the 
Venn Chart of the candidate test vs. the benchmark followed by a Venn chart comparing the benchmark test 
with the combine model (candidate test + benchmark test).   
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Figure 16 shows the impact of using the combined model with each of the example 
empirical Bayes tests.  As with the classical tests, the combined model shifted both TPs and FPs 
strongly towards that of the benchmark test, resulting in a moderate drop in TPs and a much 
sharper drop in FPs.  The impact of the combined model on TPs and FPs was similar whether 
PPIDs or spectral counts were used for the empirical Bayes test. 
 
 
Venn Chart Analysis Summary 
 
Overall, the Venn chart analysis was consistent with the F1-measure and ROC analysis in 
terms of overall test performance while highlighting an apparent partial orthogonality between 
the behavior candidate tests and the benchmark test.  On the basis of TPs, FPs, TNs and FNs, the 
benchmark test (Fisher‟s exact test on spectral counts) demonstrated a generally reduced 
 
                                                                 True Positives                               False Positives 
Figure 16.  Venn charts of the true positives and false positives generated by the classical candidate tests vs. 
the benchmark test.  A total of 115 true positives existed in the blue/green “answer key” 
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sensitivity from our candidate tests, but with a dramatically higher precision (e.g. 7 FPs for the 
benchmark test vs. 55 for empirical Bayes t-test vs. 115 maximum FPs seen for the Mann 
Whitney U test on PPID).  The benchmark also showed a moderate tendency to select for 
different TPs than the candidate tests, although the most sensitive (and least accurate) tests 
tended to identify all of the same TPs as the benchmark test.   
The Venn charts of the combined model demonstrated an ability to dramatically reduce 
the number of FPs at a minimal cost to sensitivity when the combined model is used to combine 
the candidate test with our highly precise benchmark test.  In every case, the combined model 
had more TPs than the benchmark test alone (ranging from 4 -19 more TPs than the benchmark).  
The combined model still had more FPs than the benchmark test (which only had 7 FPs) in all 
but one case (when combined with Welch‟s t-test).  Thus, the extra TPs acquired vs. the 
benchmark test by using the combined model still came at the cost of reduced precision relative 
to the benchmark test alone.   
The single case where the combined model had fewer FPs than the benchmark test alone 
helps highlight the importance of selecting tests with different performance biases when using a 
meta-analysis procedure like Fisher‟s Method.  Welch‟s t-test on PPIDs had the lowest 
sensitivity, with only 46 TPs, 40 of which were shared with the benchmark test.  Of the 19 FPs 
found by Welch‟s t-test, only one was shared with the benchmark test, leaving 6 FPs found by 
the benchmark test not found by Welch‟s t-test.  Overall, Welch‟s t-test appeared to have the 
least overlap with the benchmark test amongst all the candidate tests used in the Venn chart 
analysis.  When the two tests are combined using Fisher‟s Method, the combined model yielded 
72 TPs and only 6 FPs.  That we were able to obtain more TPs and fewer FPs by combining 
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them using Fisher‟s Method than achieved with either test alone indicates the value of using tests 
with different performance biases when using Fisher‟s Method.   
Available techniques for meta-analysis, including Fisher‟s Method, presume that the 
different classes of tests being combined are independent of each other.  If changes in protein (or 
peptide group) abundance is the topic being studied using LC-MS/MS, this would require that 
the two tests combined using Fisher‟s Method are independent of each other.  This raises the 
question of the degree of independence between the different statistical tests combined in this 
study using Fisher‟s Method.  As discussed in Chapter II, published studies comparing the use of 
spectral counts with precursor intensities for LC-MS/MS quantitation observed that both spectral 
counts and precursor intensities were potentially useful but they have different strengths and 
weaknesses (e.g. spectral counts are better for asking which proteins changed in abundance, 
precursor intensities are better at asking how much they changed in abundance).  Both methods 
suffered from erroneous abundance ratios for low-intensity proteins, albeit in different directions 
(spectral counts tended to overestimate abundance ratios while precursor intensities tended to 
overestimate abundance ratios).   
Based on those observations, spectral count-based tests and precursor ion-based tests 
could be considered at least somewhat independent of each other although the degree of 
independence remains ambiguous.  In this study, the precursor intensity data used (PPIDs) is 
directly dependent on peptide identifications, so our precursor intensity values are clearly less 
independent of the spectral count data than if we had relied exclusively on LC-MS data to 
conduct precursor intensity quantitation (as is done with tools like Corra (33)).   
In some of the cases, our combined model used p-values from two tests using spectral 
counts (e.g. the Mann Whitney U test and empirical Bayes t-test on spectral counts), and yet we 
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still observed a distinct difference between the performance of those tests and the benchmark 
test.  This suggests that some degree of independence between the tests used in our combined 
models may also arise from different biases in the statistical tests.  For instance, robustness in the 
face of missing data will vary between tests.  How the power of statistical tests changes as the 
number of replicates grows is another factor that will contribute to differences in systemic test 
biases.  All of the candidate tests in this study were parametric or non-parametric variants of the 
t-test and would therefore suffer much more from missing data points and limited replicates than 
Fisher‟s exact test which consolidates all cohort replicates into a single sum.  This could be 
particularly troublesome for the PPID-based tests in our study that would experience 
significantly more missing data points since ~25% of spectral counts were unable to be matched 
to a correlated PPID.      
 
Independence Between Candidate Tests and the Benchmark Test  
 
In order to further explore the independence and different biases of the candidate tests 
with our benchmark test, we created log2-scale plots of the ratio of spectral counts vs. the ratio of 
percentile normalized PPIDs for the Red and Yellow cohorts for each peptide group tested 
(counts and PPIDs summed for each cohort for ratio calculations).  Separate plots were created 
for each candidate test, highlighting the TP and FP peptide groups found using that test.  The TPs 
and FPs of the benchmark test are also highlighted, where the red circles indicate a TP/FP 
peptide group found only using the candidate test, a blue circle indicates a TP/FP peptide group 
found only using the benchmark test, and a purple circle shows peptide groups found using both 
the candidate and benchmark tests.   
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Example plots are 
shown in Figure 17 for 
Welch‟s t-test, the Mann 
Whitney U test (using 
percentile normalized PPIDs, 
unnormalized spectral counts, 
and normalized spectral 
counts), and  
the empirical Bayes t-
test (using PPIDs and spectral 
counts).  All tests in the 
example plots below had no 
PPID weighting or 
PPID/spectral filtering 
applied.  The plots are 
somewhat asymmetric due to 
our handling of instances 
when the Red cohort values 
(the denominator) were 0 vs. 
Yellow cohort (numerator) 
values of 0.  We chose a 
default ratio of 20 when the 
Red cohort was zero, 
 Mann Whitney U test 
(Spectral Counts) 
 Mann Whitney U test  
(% norm PPID) 
    
 PPID Log2(Yellow/Red)  PPID Log2(Yellow/Red) 
  
Mann Whitney U test 
(Normalized Spectral Counts) 
  
Welch‟s t-test  
(PPID) 
 
 
 
 
 PPID Log2(Yellow/Red)  PPID Log2(Yellow/Red) 
 Empirical Bayes t-test 
(Spectral Counts) 
 Empirical Bayes t-test 
 (PPID) 
    
 PPID Log2(Yellow/Red)  PPID Log2(Yellow/Red) 
Figure 17.  TPs for example candidate tests.  For each peptide group, the log2 
scaled ratios of the total spectral count in Red vs. Yellow cohorts (Y-axis) and the 
ratio of the total percentile normalized PPID values in Red vs. Yellow cohorts (X-
axis) was plotted.  Peptide groups accurately identified as differentially abundant 
(true positives) for both the candidate test and the benchmark test  (Fisher’s 
exact test on spectral counts) are color coded as follows:  Red = TP found only by 
the candidate test.  Blue = TP found only by the benchmark test.  Purple = TP 
found by both tests.  Relative sizes of highlighted peptide groups correspond to 
the average percentile normalized PPID values.  
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corresponding to a log2(20) ratio of ~4.3 (on either axis).  A value of zero (on either axis) 
indicates the Yellow cohort had a value of zero (spectral counts or PPIDs).   
The distribution of the TPs tended fell into two general categories:  1. Peptide groups that 
had a value of zero in either the Red or Yellow cohorts (those points at the [0,0] or laying at [0, -
log2(20)] or [log2(20), log2(20)]), and 2. Peptide groups with a non-zero value in both cohorts but 
a relatively strong difference between cohorts (i.e. peptide groups not clustered around the 
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(Spectral Counts) 
 Mann Whitney U test 
(Normalized Spectral Counts) 
 Empirical Bayes t-test 
(Spectral Counts) 
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Figure 18.  FPs for example candidate tests.  For each peptide group FP, the log2 scaled ratios of the total spectral 
count in Red vs. Yellow cohorts (Y-axis) and the ratio of the total percentile normalized PPID values in Red vs. 
Yellow cohorts (X-axis) was plotted.  Peptide groups inaccurately identified as differentially abundant (false 
positives) for both the candidate test and the benchmark test  (Fisher’s exact test on spectral counts) are color 
coded as follows:  Red = FP found only by the candidate test.  Blue = FP found only by the benchmark test.  
Purple = FP found by both tests.  Relative sizes of highlighted peptide groups correspond to the average 
percentile normalized PPID. 
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center).  Because the set was generated by excising different gel bands from two E. coli 
proteomes, we would expect many of the proteins in the answer key to have sharply different 
abundances.  In addition, the construction of our “answer key” using the “Blue/Green” data set 
used a fairly conservative test (Fisher‟s exact test using the Benjamini-Hochberg correction).   
The FPs (Figure 18) also tended to fall into two general categories:  1. Low abundance 
peptide groups with a 0 value for either the Red or Yellow, and 2. High abundant peptide groups 
with abundance ratios close to 1 (close to 0 in log2 scale).  It is not surprising that we would find 
false positives from low abundant peptides with a cohort containing a 0 value from spectral 
counts given the well-established issues spectral counts face as counts approach zero.  In our 
study, the PPIDs will have additional zero-boundary complications due to the fact that 
IDPQuantify searches for PPIDs based on spectral counts and could not find a PPID ~25% of the 
time.   
 The FPs from moderate to high abundance peptide groups with log2 abundance ratios 
close to 0 seem to represent a qualitatively different type of FP than the low abundance peptide 
groups.  Peptide groups with log2 abundance ratios close to 0 are likely to be at equal or near 
equal abundance.  Such peptide groups would be expected to yield FPs because they lie at the 
boundary separating the “no difference” peptide groups from the “mildly different” peptide 
groups.   
Interestingly, the FPs exhibited a consistent pattern between the spectral count-based tests 
and the PPID-based tests.  The PPID-based tests tended to show FPs with relatively higher PPID 
ratios than spectral count ratios (Figure 18, bottom row), whereas the spectral count-based tests 
tended to show the opposite clustering with FPs that had somewhat higher spectral count ratios 
than PPID ratios (Figure 18 top row).  This pattern was apparent when comparing the same test 
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run on either PPIDs or spectral counts (e.g. the empirical Bayes t-test and the Mann Whitney U 
test), indicating that different biases in the candidate tests were not the sole cause of this pattern.  
This observation suggests a partial degree of independence between the information provided by 
spectral counts and precursor intensities.   
It is worth noting that sets of TPs and FPs both had a large number of peptide groups with 
zero spectral counts or PPIDs in either the Red or Yellow cohorts, but the TPs with a zero-cohort 
tended to be moderately more abundant than the FPs (larger circles in the TP plots at the center 
or ~4.3 on either axis vs. tiny circles in the FP plots).  This is consistent with the observation 
above that minimum PPID/spectral filtering tended to mildly improve test performance when a 
filter of 5 or 10 PPID/spectral counts was applied but higher filters began to detrimentally impact 
the candidate tests‟ performance.   
 
Evaluation of Peptide Group-Level Difference Testing 
 
For Specific Aim III, we sought to establish the validity of difference testing at the 
peptide group-level.  Because difference testing at the peptide group-level avoids the step of 
normalizing spectral counts (or PPIDs) for each individual protein in a protein group (which may 
vary in size or sequence coverage), we would like to show that peptide group-level difference 
testing will be able to appropriately handle the issue of peptides in a given peptide group being 
shared amongst the proteins in their respective associated protein groups.   
Bipartite graphs of the peptide groups and protein groups from four example candidate 
tests are shown below (Figure 19).  Each graph is shown for the candidate test alone, without the 
combined model applied.  Each candidate test‟s graph shows the peptide groups and protein 
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groups from all protein group clusters that contain a single peptide group found to be 
differentially abundant (TPs and FPs).  Unshared peptide groups and associated protein groups 
are not shown.  Circles represent protein groups, triangles represent peptide groups (TP, FN, 
TN), and squares represent FP peptide groups.  White triangles accepted the null hypothesis.  
Triangles and squares that reject the null hypothesis (i.e. TPs and FPs) are colored yellow-to-
black, with yellow the least significant and black most significant of the declared TPs.  As shown 
in the figures, the differentially abundant peptide groups were almost exclusively amongst 
unshared peptide groups.   
Of the four bipartite graphs shown in Figure 19, only four shared peptide groups rejected 
the null hypothesis.  Three out of those four shared peptide groups were FPs, with the sole TP 
shared peptide group found by Fisher‟s exact test.  If a shared peptide group is found to be 
differentially abundant, than we would expect at least one of associated protein groups to have an 
unshared peptide group that also rejects the null hypothesis.  This was not the case for the either 
of the unshared peptide groups connected to the protein groups associated with the shared 
peptide group identified by Fisher‟s exact test.  These unshared peptide groups were not FNs 
either (FN data not shown), raising the possibility that this peptide group is in the “answer key” 
erroneously.  Regardless, that three out of four of the shared peptide groups were FPs suggests  
that unshared peptide groups are a far less error prone than shared peptide groups, as would be 
expected.  
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An additional observation is that the FPs tended to be among the least significant of those 
peptide groups that rejected the null hypothesis (i.e. more yellow than black).   This may 
partially explain the apparent gains in performance that came from applying Fisher‟s Method in 
our combined model.  If FPs tend to have less significant p-values, they are more prone to being 
eliminated by a technique like Fisher‟s Method. 
 
 
 
 
Figure 19.  The peptide groups and associated protein groups from example candidate tests showing p-values 
significance levels and FPs for each protein group cluster contain at least one peptide group yielding a 
significant test result.  Circles represent protein groups, triangles represent peptide groups (TP, FN, TN), and 
squared represent FP peptide groups.  White triangles accepted the null hypothesis.  TPs and FPs are colored 
yellow-to-black, with yellow the least significant and black most significant of the declared TPs.   
Fisher‟s exact test Welch‟s t-test 
Empirical Bayes t-test (spectral counts) 
 
Empirical Bayes t-test w/ arcsine(sqrt) on % 
normalized  (PPID) 
 
70 
 
 
Summary and Further Discussion 
 
In this chapter, we used the iPRG 2009 Study E. coli LC-MS/MS data set to compare and 
contrast the performance of statistical difference testing at the peptide group level using either 
spectral counts or precursor ion intensities separately.  We also examine the use of two PPID-
weighting techniques to account for missing PPIDs and two spectral count/PPID filtering 
techniques to eliminate peptide groups with few data points.  Using the F1-measure and ROC 
analysis as our performance metrics and Fisher‟s exact test (on spectral counts) as our 
benchmark, we first observed that no test could surpass the benchmark test‟s ability to identify 
69 out of 115 TPs with only 7 FPs.  Most of the candidate tests were able to find more TPs, but 
at the cost of significantly more FPs.  Both weighting techniques showed moderate increases or 
decreases to test performance inconsistently.  The filtering methods both showed mildly positive 
results when filters were set to exclude only those peptide groups with fewer than 5 or 10 PPIDs 
or spectral counts per cohort (or across both cohorts) 
When candidate tests were combined with the benchmark test using Fisher‟s Method (our 
combined model), we observed a sharp drop in FPs with only a moderate drop in TPs relative to 
the candidate tests alone.  These promising results required further investigation because Fisher‟s 
Method, or other meta-analysis techniques, requires the separate p-values to be independent of 
each other.  The PPID values used in this study were generated using identified spectra as a 
starting point, so the PPIDs and spectral count values could not be fully independent in our 
study.  At the same time, the extremely high precision of the benchmark test compared to the 
candidate tests suggests the benchmark test had a distinctly different bias towards not accepting 
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FPs exhibited by the other candidate tests when either spectral counts or PPIDs were used for the 
candidate tests.  Venn chart analysis comparing the TPs and FPs of candidate tests with our 
benchmark test also indicate that the benchmark test was also selecting for an overlapping, but 
still distinctly different TPs than then other tests.  These observations indicate that spectral count 
and PPID data contain both mutual information but also orthogonal information since there are 
some TPs and FPs found exclusively using spectral counts and some found only using PPIDs.      
The partial independence between PPIDs and spectral counts may results in moderately 
different abundance ratios, but that moderate difference can result in qualitatively different 
statistical test results.  This is highlighted by the plots of the log2 ratio between the Red and 
Yellow cohorts of spectral counts (y-axis) and PPIDs (x-axis).  The log2 ratio plots of FPs 
demonstrated a tendency of PPID-based statistical tests to yield FPs with low PPID ratios, but 
even lower spectral count ratios.  Similarly, spectral count-based candidate tests yielded FPs with 
low spectral count ratios, but even lower PPID ratios.  For these peptide groups with equal or 
nearly equal abundances, a modest independence in the spectral count data and PPID data may 
result in a rejection of the null hypothesis with one data type and acceptance of the null 
hypothesis with the other.   
Old et al. observed a similar pattern when they statistically tested for differentially 
abundant proteins using either precursor intensities or spectral counts.  They found most of 
proteins that were found to be differentially abundant when using precursor intensities but not 
when using spectral counts were proteins with low abundance ratios.  They also found that a 2.3 
fold change was the smallest fold change they could identify with 95% confidence using 
precursor peak abundance(11).  Their findings underscore the greater difficulty in difference 
testing faced as the abundance ratio approaches 1.   
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Our results strongly suggest that our combined model can give researchers a powerful 
new approach of combining the results from two statistical tests with different biases into a 
single hybrid test that exhibits properties of both constituent tests.  In particular, we 
demonstrated that combining the results of a conservative test (high precision, lower sensitivity) 
with more sensitive but less precise tests resulted in hybrid tests that exhibited enhanced 
sensitivities with a moderate cost to precision over the conservative test.  This approach could be 
useful in experiments where researchers are willing to accept a moderate level of FPs in order to 
identify more TPs but still want to avoid the large numbers of TPs yielded by many quantitative 
methods.   
 It is also worth noting that the performance of our candidate tests was similar to the 
results of iPRG 2009 Study.   In the study, the iPRG 2009 E. coli data set was distributed to 
multiple proteomics groups (52).  Each group was asked to identify the differentially abundant 
proteins using any method of their choice and return their results the study authors to compare 
the performances of the different approaches.  Each group‟s test performance was evaluated at 
multiple error rate thresholds (1%, 5%, 10%, and 25%).  The authors found that groups using 
spectral counts consistently correctly identified more differentially abundant proteins at all 
thresholds due to the high error rates seen for groups using precursor intensities.  The one 
exception was at the 25% error rate threshold where a group using precursor intensities had the 
top performance.  As the authors pointed out, the use of precursor intensities also requires more 
experience than spectral count methods and many of the protein differences in the iPRG 2009 
Study data set were much stronger than would be expected for biological samples.  Both of these 
points suggest that the number of FPs generated by precursor intensity-based methods in 
biomarker studies will be an ongoing challenge going forward.  Consistent with the iPRG 2009 
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Study, our evaluations of the separate candidate tests found our benchmark test, Fisher‟s exact 
test on spectral counts, to be more conservative than any of the PPID-based tests.  Fisher‟s exact 
test is thus an excellent statistical test to pair with precursor intensity-based tests for researchers 
interested in a statistical test less conservative than Fisher‟s exact test but more conservative than 
available the is cat precursor intensity-based methods.   
We also addressed the feasibility of difference testing at the peptide group-level as 
opposed to the protein level as is normally done, as specified in Specific Aim III.  We found few 
shared peptides groups that yielded rejected null hypotheses, and those that did reject the null 
hypothesis were largely false positives.  We also observed that the false positives tended to have 
less significant p-values than that the true positives.  This demonstrates the utility of peptide 
group analysis when using the combined model if false positives tend to have the less significant 
p-values amongst the peptide groups with rejected null hypothesis.  Overall, it appears that 
peptides belonging to shared peptide groups should be ignored in quantitative analysis, whereas 
quantitative data from peptides belonging to an unshared peptide group should be retained and 
used for quantitative analysis.  The peptides in an unshared peptide group are still shared 
peptides, but shared only between the proteins in a single protein-group (unless there is only a 
single peptide or single protein in the peptide group and protein group).  This method of rejecting 
quantitative peptide data from shared peptide groups and only using unshared peptide group data 
represents a novel form of grouping and filtering quantitative data from shared peptides. 
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CHAPTER V 
 
CONCLUSION AND FUTURE WORK 
 
Advances in mass spectrometry have resulted in enormous improvements in both the 
quality and quantity of LC-MS/MS data.  But unlocking the full biological knowledge that can 
be learned from that data will require new methodologies of quantitative analysis and statistical 
techniques.  We hypothesized that enhanced proteomic difference testing can be achieved by 
combining spectral count data with precursor intensity data (labeled our “combined model” in 
this study).  We also hypothesized that difference testing at the peptide group-level provided a 
viable means of group peptides and filtering out noise from shared peptides.   To achieve this, we 
had three specific aims:  I. To compare performance and independence of difference testing 
using spectral count and precursor intensities alone; II. To compare the performance of 
difference testing using Fisher‟s Method to combine p-values of PPID and spectral count-based 
statistical tests vs. difference testing using each data type alone; and III. To establish the validity 
of difference testing at the peptide group-level vs. the protein level.  All three specific aims were 
accomplished in this study and both of our hypotheses were validated.   
Specific Aim I was enabled by the development of IDPQuantify (Chapter III), which 
provided peptide group-level spectral count and precursor intensity data in the form of PPIDs.  
The iPRG 2009 E. coli data set with a known “answer key” was then used to evaluate and 
compared the statistical test alone (Chapter IV).   A variety of candidate statistical tests using 
either PPIDs or spectral counts were chosen for this analysis.  We found that spectral count-
based testing using our benchmark test (Fisher‟s exact test on spectral counts) provided superior 
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specificity, but reduced sensitivity compared to PPID-based tests.  The PPID-based test, 
conversely, had greater potential sensitivity, but at the cost of far more FPs than Fisher‟s exact 
test.   
The orthogonality and mutual information contained in spectral count and PPID data was 
further characterized using Venn chart analysis and cohort abundance ratio analysis.  Venn chart 
analysis showed distinctly different sets of TPs and FPs that were likely to be yielded using 
spectral count or PPID-based tests.  Using the abundance ratio plots, we observed that the set FPs 
for all tests contained a large number of low-abundant peptide groups, regardless of whether 
spectral counts or PPIDs were used.  Among the more abundant FPs, however, a pattern emerged 
distinguishing the spectral count tests and PPID tests.  The more abundant FPs generated by 
spectral count-based tests tended to have a low spectral count ratio, but an even lower PPID 
ratio.  For PPID-based tests, the opposite pattern was seen.  This suggested that a given LC-
MS/MS data set is going to contain a mix of peptide groups that are likely to trigger FPs from 
spectral count methods, but not precursor intensity methods, and vice versa.   
For Specific Aim II, we then evaluated our combined model for difference testing to the 
candidate tests alone.  This model was shown to create hybrid statistical results that tended to 
eliminate weakly rejected null hypotheses from either test, while retaining the most strongly 
rejected null hypotheses.  When candidate statistical tests were combined with the more 
conservative Fisher‟s exact tests, the results were a modest drop in sensitivity but much sharper 
drop in the error rate (relative to the candidate test alone).  This appears to be due, in part, to the 
erroneously rejected null hypothesis (FPs) tending to have less significant p-values (e.g. closer to 
0.05 than 0) (Figure 19).  Thus, FPs generated by the candidate tests were more likely to be 
discarded when using Fisher‟s method than true positives (TPs).   
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For Specific Aim III, the analysis of peptide group-level difference testing in place of 
protein-level difference testing, consisted of viewing the tendency of shared peptide groups and 
unshared peptide groups to yield FPs.  In the four candidate test examples shown in Figure 31, 
there were a total of four shared peptide groups total with rejected null hypotheses, three of 
which were FPs.  This indicates that peptides that are shared across multiple protein groups are a 
greater source of error than peptides shared only across proteins in a single protein group. and 
calls for relying primarily on peptides from unshared peptide groups for difference testing.  
While we conducted our difference testing without normalizing each protein individually (such 
as using NSAF or emPAI), peptide group level analysis may still be useful to researchers that 
desire protein-specific normalization.   Following the grouping of peptides into peptide groups 
and the discarding of quantitative data from shared peptide groups, researchers are still free to 
further normalize each protein individually.  As discussed previously, however, conducting a 
separate test for each protein in a protein group raises issues of independence and expands the 
total number of tests conducted.  A greater number of tests can lead to additional type I errors 
and conflicts with multiple testing correction procedures, such as the Benjamini-Hochberg 
procedure. 
Independence of tests is also a requirement for the application of Fisher‟s Method.  Our 
spectral count and precursor intensity data were clearly not independent since precursor 
intensities, in the form of PPIDs, were derived from spectral counts.  But while the spectral count 
and PPID data in this study may not have been fully independent, the behavior of spectral count 
and PPID-based tests explored in Specific Aim I suggests that spectral counts and PPIDs were 
independent enough for our combined model to yield useful results.     
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Overall, we established that the use of spectral count or precursor intensities for 
difference testing involves a tradeoff between the more sensitive precursor-based approach and 
the more accurate spectral count-based approach.  These differences in test performance were 
due, in part, to differences the underlying data but also the types of tests available for each data 
type (e.g. parametric vs. non-parametric).  We also established that these differences in test 
performance included overlapping, but still distinct sets of TPs and FPs obtained when using 
either metric.  We then demonstrated that our combined model gives researchers a tool for 
creating hybrid statistical result sets that tended to have a slight drop in sensitivity from the 
PPID-based tests along with a sharp drop in FPs.  The FPs, in turn, tended to have the least 
significant p-values among the rejected null hypotheses, making them more likely to be 
discarded upon application of our combined model.  We also demonstrated that peptide group-
level analysis is effective at segregating peptides into noisier shared peptide groups and less 
noisy unshared peptide groups.  
An obvious area for future work involves using precursor intensities that were truly 
generated independently from spectral counts.  This could involve the use of peak alignment 
strategies on LC-MS data to extract precursor intensities without any knowledge of peptide 
identification.  In addition to making the two types of data more independent of each other, peak 
alignment strategies for precursor intensity generation would likely improve the performance of 
tests relying on precursor intensities given the difficulty many parametric tests face with missing 
data points.  Any method that improves either precursor intensity-based testing or spectral count-
based testing alone will also improve the results from our combined model.  Thus, the 
performance of the combined model using improved de-noising, normalization, or data 
imputation strategies for missing data is something to be explored.   
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Another issue needing further analysis is the use of our combined model on more 
complicated data sets with less striking differences in abundance.  As discussed in Chapter IV, 
the method for creating the iPRG 2009 Study data set resulted in more pronounced differences in 
abundance for the TPs than would be normally expected.  In data sets involving fewer TPs with 
less prominent changes, many TPs found by a single test may be only weakly significant (i.e. a 
p-value close to 0.05) and Fisher‟s Method may result in the erroneous rejections.  In such a 
case, the pairing of two sensitive, but less conservative, tests using Fisher‟s Method may be 
advised.   
Alternatively, more than two tests could be combined to provide a larger number of p-
value “votes” for each peptide group.  Three or more tests will result at least two tests sharing 
either precursor intensities or spectral counts, so this approach would come with the added 
caveat of a lack of independence.  Two tests using the same data type, however, may still be 
partially independent if the tests follow very different statistical assumptions or biases.  For 
instance, while the Mann Whitney U test and Fisher‟s exact test can both be run on spectral 
counts, the Mann Whitney U test suffers much more from few replicates than Fisher‟s exact test.  
The extent to which different statistical tests behave independently when run on the same data is 
an important question for applying this combined model to proteomic quantitation. 
The application of the combined model to protein-level difference testing rather than 
peptide group difference testing could also be evaluated.  One of the disadvantages of peptide 
group-level difference testing over protein-level difference testing is that peptide group-level 
difference test will generally use less information (i.e. less peptide-specific quantitative data 
points) than if the test was conducted at the level of individual proteins and shared peptides are 
accounted handled instead of discarded.  The impact of the peptide group-level information 
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dilution needs to be addressed with for species with more complex proteomes.  Humans, for 
instance, will have far more shared peptide groups than E. coli and more overall protein 
identifications.  This dilutes the amount of sampling that can be conducted per-protein, resulting 
in fewer proteins per peptide group.  At the same time, because human proteins tend to have 
more isoforms than E. coli, the protein groups will likely consist of more individual proteins.  
Thus, strategies that divide spectral count data between shared proteins may end up with little 
signal for each of the separate protein tests.    In addition, the potential lack of independence if 
quantitative data is shared for multiple proteins (as in the original NSAF method) would need to 
be addressed.  Applying the combined model to protein-level difference testing also raises the 
issue of extra non-independent tests compared to peptide group-level testing when employing 
multiple testing correction procedures.   
The potential lack of independence between tests begs for more understanding of how to 
best control the FDR using our combined model.  The Benjamini-Hochberg procedure used in 
this study assumed independence and focuses on controlling for the PCER instead of the FWER.  
Non-independent tests may end up causing more extreme p-values after Fisher‟s Method is 
applied, in particular if more than two non-independent p-values are to be combined and multiple 
p-values rely on the same data (spectral counts or precursor intensities).  In such a case, using a 
more conservative FWER procedure to control the FDR may be in order.    
Another approach may be to use a procedure that does not assume independence, such as 
the positive False Discovery Rate (pFDR) method using q-values developed by Storey et. al (53). 
As the authors pointed out, an advantage of the pFDR over the Benjamini-Hochberg correction is 
that the Benjamini-Hochberg correction attempts to control the FDR for all tests, whereas the 
pFDR procedure only attempts to control for FDR among those tests that resulted in a rejected 
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null hypothesis.  This makes the pFDR much less conservative in instances when few null 
hypotheses are rejected.  For more complex data sets with subtler shifts in abundance the pFDR 
procedure may be a better choice than Benjamini-Hochberg.   
Biomarker detection is an area where our combined model could be especially useful.  
Striking a balance between sensitivity and accuracy is important for such studies and our model 
could enable researchers with greater flexibility in modulating the performance characteristics of 
their tests.  Our combined model assumes two tests, one on spectral counts and one on precursor 
intensities, leaving a great deal of discretion to the researcher in determining which statistical 
tests to use and what type of normalization and FDR controlling procedures are employed.  For 
each of the two tests, there is a tradeoff between the sensitivity and power of the tests coupled 
with the strength of the FDR controlling procedure.  The results of these choices are further 
coupled when the test p-values are combined using Fisher‟s Method.  Just this simple two-test 
scenario leaves many possible permutations of pairs of tests coupled with FDR methods that 
have yet to be evaluated.   
Another possible application of our combined model is the improved detection of low 
concentration proteins that change in abundance.  As described in Chapter II, published studies 
indicate that both spectral count and precursor intensity-based methods suffer higher error rates 
for low-abundant proteins.  Our combined model may be able to reduce that error rate by 
providing a second piece of evidence for each protein testing.  Furthermore, by conducting 
difference testing at the peptide-group level, we may be better suited to accurately test low-
abundance proteins.  Peptide group-level difference testing separates the less-reliable data from 
shared peptide groups from the more reliable data from unshared peptide groups.  Subsequent 
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testing of the unshared peptide group data together, instead of diluting it further as shared 
peptides, could be particularly useful for low abundance proteins where the signal is limited.   
Label-free proteomic quantitation using LC-MS/MS data has been a challenging area of 
research for many years.  The data acquired are noisy and complex and are nowhere near as 
noisy or complex as the biological systems being studied.  For LC-MS/MS to remain an 
invaluable tool to researchers, new methods will need to be developed to keep pace with the new 
investigative demands of the research community.  In this study we presented two such new 
methods and a new tool enabling those methods.  It is hoped that the methods introduced in this 
study will enable researchers to gain more real insights from their data with fewer errors.   
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Supplemental File 1.  MyriMatch Search Configuration Parameters 
 
MyriMatch search parameters for iPRG 2009 E. coli LC-MS/MS data set were as follows: 
 
CleavageRules = [|[M|K|R . . ] 
NumMinTerminiCleavages = 1 
CalculateRelativeScores = 0 
DynamicMods = M * 15.994915 (Q! % -17.026549 C & 57.021464 
AdjustPrecursorMass = true  
MinPrecursorAdjustment = -1.008665  
MaxPrecursorAdjustment = 1.008665  
PrecursorAdjustmentStep = 1.008665  
NumSearchBestAdjustments = 3 
PrecursorMzTolerance = 0.1 
FragmentMzTolerance = 0.5 
TicCutoffPercentage = 0.95 
UseAvgMassOfSequences = 0 
UseChargeStateFromMS = 1 
NumChargeStates = 5 
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Supplemental File 2.  F1-Measures for Candidate Tests  
 
Table S2.1  F1-Measures For Classical Tests Using the “Minimum Spectral Count/PPID in at least 
one cohort” filter 
 
Minimum Spectral Count/PPID in at least one cohort 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark Test) 0.70 0.70 0.70 0.70 0.64 0.62 
Student's t-test on PPIDs 0.60 0.60 0.61 0.58 0.52 0.46 
Student's t-test log transformation on 
PPIDs 0.55 0.55 0.58 0.50 0.44 0.38 
Welch's t-test on PPIDs 0.49 0.49 0.50 0.43 0.41 0.31 
Welch's t-test log transformation on 
PPIDs 0.55 0.55 0.55 0.46 0.42 0.36 
Mann Whitney U test on Spectral 
Counts 0.58 0.60 0.65 0.66 0.62 0.59 
Modified Mann Whitney U test on 
Spectral Counts 0.64 0.65 0.70 0.72 0.67 0.63 
Mann Whitney U test on PPIDs 0.58 0.59 0.65 0.67 0.65 0.61 
 
 
Table S2.2  F1-Measures For Classical Tests Using the “Minimum Spectral Count/PPID across 
both cohorts” filter 
 
Minimum Spectral Count/PPID across both cohorts 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark Test) 0.70 0.70 0.70 0.70 0.70 0.70 
Student's t-test on PPIDs 0.60 0.60 0.61 0.59 0.56 0.46 
Student's t-test log transformation on 
PPIDs 0.55 0.55 0.58 0.52 0.47 0.40 
Welch's t-test on PPIDs 0.49 0.49 0.50 0.46 0.45 0.34 
Welch's t-test log transformation on 
PPIDs 0.55 0.55 0.54 0.46 0.43 0.38 
Mann Whitney U test on Spectral 
Counts 0.58 0.58 0.58 0.58 0.58 0.58 
Modified Mann Whitney U test on 
Spectral Counts 0.64 0.64 0.64 0.64 0.64 0.64 
Mann Whitney U test on PPIDs 0.58 0.60 0.61 0.62 0.64 0.61 
 
 
Table S2.3  F1-Measures For Combined Model (Classical Tests + Benchmark) Using the 
“Minimum Spectral Count/PPID in at least one cohort” filter 
 
Minimum Spectral Count/PPID in at least one cohort 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.70 0.70 0.70 0.70 0.64 0.62 
Student's t-test on PPIDs 0.71 0.70 0.72 0.71 0.69 0.67 
Student's t-test log transformation on 
PPIDs 0.70 0.70 0.71 0.69 0.68 0.66 
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Welch's t-test on PPIDs 0.72 0.72 0.72 0.71 0.69 0.67 
Welch's t-test log transformation on 
PPIDs 0.70 0.70 0.70 0.68 0.68 0.66 
Mann Whitney U test on Spectral 
Counts 0.70 0.70 0.73 0.73 0.71 0.68 
Modified Mann Whitney U test on 
Spectral Counts 0.71 0.71 0.73 0.73 0.72 0.69 
Mann Whitney U test on PPIDs 0.72 0.72 0.74 0.74 0.73 0.70 
 
 
 
Table S2.4  F1-Measures For Combined Model (Classical Tests + Benchmark) Using the 
“Minimum Spectral Count/PPID across both cohorts” filter 
  Minimum Spectral Count/PPID across both cohorts 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.70 0.70 0.70 0.70 0.70 0.70 
Student's t-test on PPIDs 0.71 0.70 0.72 0.72 0.71 0.69 
Student's t-test log transformation on 
PPIDs 0.70 0.70 0.72 0.70 0.70 0.68 
Welch's t-test on PPIDs 0.72 0.72 0.72 0.71 0.71 0.69 
Welch's t-test log transformation on 
PPIDs 0.70 0.70 0.70 0.69 0.69 0.68 
Mann Whitney U test on Spectral 
Counts 0.70 0.70 0.70 0.70 0.70 0.70 
Modified Mann Whitney U test on 
Spectral Counts 0.71 0.71 0.71 0.71 0.71 0.71 
Mann Whitney U test on PPIDs 0.72 0.72 0.74 0.74 0.72 0.70 
 
 
Table S2.5  F1-Measures For Empirical Bayes t-test Using the “Minimum Spectral Count/PPID in 
at least one cohort” filter 
  Minimum Spectral Count/PPID in at last one cohort 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.70 0.70 0.70 0.70 0.64 0.62 
empirical Bayes on PPIDs 0.63 0.65 0.66 0.63 0.59 0.49 
empirical Bayes on PPIDs + missed 
PPID weighting 0.61 0.66 0.63 0.62 0.57 0.50 
empirical Bayes on PPIDs + observed 
PPID weighting 0.62 0.66 0.65 0.62 0.58 0.49 
empirical Bayes on PPIDs + log 
normalization 0.58 0.58 0.61 0.53 0.50 0.42 
empirical Bayes on PPIDs + log 
normalization + missed PPID 
weighting 0.57 0.58 0.62 0.56 0.51 0.44 
empirical Bayes on PPIDs + log 
normalization + observed PPID 
weighting 0.56 0.59 0.62 0.55 0.51 0.45 
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empirical Bayes on PPIDs + 
percentile normalization 0.66 0.65 0.69 0.64 0.59 0.49 
empirical Bayes on PPIDs + 
percentile normalization + missed 
PPID weighting 0.69 0.65 0.67 0.64 0.58 0.49 
empirical Bayes on PPIDs + 
percentile normalization + observed 
PPID weighting 0.64 0.65 0.71 0.67 0.62 0.51 
empirical Bayes on PPIDs + 
percentile+arcsine(sqrt) 
normalization 0.65 0.66 0.70 0.66 0.59 0.49 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
missed PPID weighting 0.67 0.66 0.69 0.64 0.58 0.49 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
observed PPID weighting 0.66 0.66 0.72 0.67 0.61 0.51 
empirical Bayes on PPIDs + max 
value normalization 0.49 0.49 0.49 0.49 0.48 0.43 
empirical Bayes on PPIDs + max 
value normalization + missed PPID 
weighting 0.50 0.50 0.50 0.50 0.49 0.44 
empirical Bayes on PPIDs + max 
value normalization + observed PPID 
weighting 0.45 0.44 0.47 0.48 0.48 0.43 
empirical Bayes on PPIDs + max 
value normalization + log 
transformation 0.56 0.53 0.54 0.51 0.49 0.43 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + missed PPID 
weighting 0.55 0.53 0.54 0.52 0.50 0.45 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + observed PPID 
weighting 0.56 0.51 0.53 0.49 0.48 0.43 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) 0.50 0.48 0.50 0.49 0.47 0.42 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
missed PPID weighting 0.50 0.48 0.52 0.50 0.49 0.43 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
observed PPID weighting 0.44 0.44 0.48 0.48 0.48 0.43 
empirical Bayes on Spectral Counts 0.67 0.69 0.72 0.70 0.65 0.60 
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Table S2.6  F1-Measures For Empirical Bayes t-test Using the “Minimum Spectral Count/PPID 
across both cohorts” filter 
  Minimum Spectral Count/PPID across both cohorts 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.70 0.70 0.70 0.70 0.70 0.70 
empirical Bayes on PPIDs 0.63 0.65 0.64 0.63 0.60 0.53 
empirical Bayes on PPIDs + missed 
PPID weighting 0.61 0.63 0.64 0.62 0.59 0.52 
empirical Bayes on PPIDs + observed 
PPID weighting 0.62 0.66 0.65 0.63 0.60 0.52 
empirical Bayes on PPIDs + log 
normalization 0.58 0.59 0.61 0.55 0.52 0.44 
empirical Bayes on PPIDs + log 
normalization + missed PPID 
weighting 0.57 0.59 0.61 0.55 0.51 0.44 
empirical Bayes on PPIDs + log 
normalization + observed PPID 
weighting 0.56 0.56 0.60 0.57 0.53 0.45 
empirical Bayes on PPIDs + 
percentile normalization 0.66 0.65 0.65 0.63 0.59 0.51 
empirical Bayes on PPIDs + 
percentile normalization + missed 
PPID weighting 0.69 0.65 0.66 0.62 0.58 0.52 
empirical Bayes on PPIDs + 
percentile normalization + observed 
PPID weighting 0.64 0.65 0.69 0.62 0.62 0.53 
empirical Bayes on PPIDs + 
percentile+arcsine(sqrt) 
normalization 0.65 0.65 0.65 0.65 0.66 0.62 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
missed PPID weighting 0.67 0.64 0.65 0.65 0.66 0.62 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
observed PPID weighting 0.66 0.64 0.65 0.65 0.66 0.60 
empirical Bayes on PPIDs + max 
value normalization 0.49 0.49 0.48 0.47 0.46 0.42 
empirical Bayes on PPIDs + max 
value normalization + missed PPID 
weighting 0.50 0.49 0.49 0.48 0.46 0.42 
empirical Bayes on PPIDs + max 
value normalization + observed PPID 
weighting 0.45 0.44 0.45 0.45 0.44 0.40 
empirical Bayes on PPIDs + max 
value normalization + log 
transformation 0.56 0.53 0.54 0.50 0.47 0.44 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + missed PPID 
weighting 0.55 0.53 0.54 0.50 0.47 0.45 
empirical Bayes on PPIDs + max 
value normalization+log 0.56 0.54 0.52 0.49 0.47 0.42 
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transformation + observed PPID 
weighting 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) 0.50 0.48 0.49 0.47 0.45 0.41 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
missed PPID weighting 0.50 0.48 0.49 0.47 0.46 0.42 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
observed PPID weighting 0.44 0.44 0.45 0.44 0.44 0.40 
empirical Bayes on Spectral Counts 0.67 0.67 0.67 0.67 0.67 0.67 
 
 
Table S2.7  F1-Measures For Combined Model (Empirical Bayes t-test + Benchmark) Using the 
“Minimum Spectral Count/PPID at least one cohort” Filter 
  Minimum Spectral Count/PPID across at least one cohort 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.70 0.70 0.70 0.70 0.64 0.62 
empirical Bayes on PPIDs 0.73 0.72 0.72 0.71 0.69 0.67 
empirical Bayes on PPIDs + missed 
PPID weighting 0.71 0.72 0.72 0.71 0.68 0.67 
empirical Bayes on PPIDs + observed 
PPID weighting 0.70 0.70 0.69 0.70 0.69 0.67 
empirical Bayes on PPIDs + log 
normalization 0.70 0.69 0.73 0.71 0.70 0.67 
empirical Bayes on PPIDs + log 
normalization + missed PPID 
weighting 0.69 0.68 0.71 0.71 0.70 0.67 
empirical Bayes on PPIDs + log 
normalization + observed PPID 
weighting 0.68 0.69 0.72 0.71 0.69 0.68 
empirical Bayes on PPIDs + 
percentile normalization 0.74 0.72 0.74 0.72 0.69 0.67 
empirical Bayes on PPIDs + 
percentile normalization + missed 
PPID weighting 0.74 0.72 0.75 0.73 0.70 0.68 
empirical Bayes on PPIDs + 
percentile normalization + observed 
PPID weighting 0.74 0.72 0.74 0.73 0.72 0.69 
empirical Bayes on PPIDs + 
percentile+arcsine(sqrt) 
normalization 0.72 0.70 0.74 0.72 0.69 0.67 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
missed PPID weighting 0.72 0.71 0.75 0.73 0.71 0.68 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
observed PPID weighting 0.71 0.72 0.75 0.73 0.72 0.69 
empirical Bayes on PPIDs + max 
value normalization 0.61 0.62 0.61 0.62 0.62 0.61 
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empirical Bayes on PPIDs + max 
value normalization + missed PPID 
weighting 0.61 0.61 0.61 0.61 0.62 0.61 
empirical Bayes on PPIDs + max 
value normalization + observed PPID 
weighting 0.58 0.57 0.59 0.60 0.61 0.59 
empirical Bayes on PPIDs + max 
value normalization + log 
transformation 0.73 0.69 0.69 0.68 0.66 0.64 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + missed PPID 
weighting 0.72 0.68 0.67 0.65 0.65 0.64 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + observed PPID 
weighting 0.72 0.67 0.69 0.66 0.66 0.65 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) 0.60 0.59 0.62 0.62 0.63 0.61 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
missed PPID weighting 0.60 0.58 0.62 0.61 0.62 0.60 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
observed PPID weighting 0.59 0.57 0.59 0.59 0.60 0.58 
empirical Bayes on Spectral Counts 0.73 0.74 0.75 0.74 0.73 0.69 
 
 
Table S2.8  F1-Measures For Combined Model (Empirical Bayes t-test + Benchmark) Using the 
“Minimum Spectral Count/PPID across both cohorts” Filter 
  Minimum Spectral Count/PPID across both cohorts 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.70 0.70 0.70 0.70 0.70 0.70 
empirical Bayes on PPIDs 0.73 0.71 0.71 0.72 0.71 0.68 
empirical Bayes on PPIDs + missed 
PPID weighting 0.71 0.71 0.72 0.71 0.70 0.68 
empirical Bayes on PPIDs + observed 
PPID weighting 0.70 0.70 0.71 0.69 0.68 0.67 
empirical Bayes on PPIDs + log 
normalization 0.70 0.70 0.73 0.72 0.72 0.69 
empirical Bayes on PPIDs + log 
normalization + missed PPID 
weighting 0.69 0.69 0.72 0.70 0.70 0.68 
empirical Bayes on PPIDs + log 
normalization + observed PPID 
weighting 0.68 0.69 0.72 0.70 0.71 0.68 
empirical Bayes on PPIDs + 
percentile normalization 0.74 0.72 0.74 0.74 0.71 0.68 
empirical Bayes on PPIDs + 
percentile normalization + missed 0.74 0.73 0.74 0.74 0.71 0.70 
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PPID weighting 
empirical Bayes on PPIDs + 
percentile normalization + observed 
PPID weighting 0.74 0.73 0.73 0.73 0.71 0.70 
empirical Bayes on PPIDs + 
percentile+arcsine(sqrt) 
normalization 0.72 0.72 0.73 0.73 0.72 0.69 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
missed PPID weighting 0.72 0.72 0.74 0.74 0.72 0.71 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
observed PPID weighting 0.71 0.73 0.72 0.71 0.71 0.70 
empirical Bayes on PPIDs + max 
value normalization 0.61 0.62 0.61 0.61 0.61 0.60 
empirical Bayes on PPIDs + max 
value normalization + missed PPID 
weighting 0.61 0.60 0.60 0.61 0.60 0.60 
empirical Bayes on PPIDs + max 
value normalization + observed PPID 
weighting 0.58 0.57 0.58 0.58 0.59 0.58 
empirical Bayes on PPIDs + max 
value normalization + log 
transformation 0.73 0.68 0.71 0.70 0.68 0.66 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + missed PPID 
weighting 0.72 0.69 0.69 0.68 0.66 0.64 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + observed PPID 
weighting 0.72 0.69 0.68 0.67 0.67 0.65 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) 0.60 0.60 0.61 0.61 0.61 0.60 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
missed PPID weighting 0.60 0.59 0.61 0.61 0.60 0.59 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
observed PPID weighting 0.59 0.58 0.59 0.58 0.58 0.57 
empirical Bayes on Spectral Counts 0.73 0.73 0.73 0.73 0.73 0.73 
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Supplemental File 3.  ROC curve AUCs for Candidate Tests  
 
Table S3.1  AUCs For Classical Tests Using the “Minimum Spectral Count/PPID in at least one 
cohort” filter 
  Minimum Spectral Count/PPID in at least one cohort 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.85 0.88 0.87 0.85 0.82 0.81 
Student's t-test on PPIDs 0.87 0.88 0.87 0.83 0.80 0.77 
Student's t-test log transformation on 
PPIDs 0.86 0.88 0.86 0.83 0.81 0.77 
Welch's t-test on PPIDs 0.87 0.88 0.86 0.83 0.80 0.77 
Welch's t-test log transformation on 
PPIDs 0.86 0.87 0.86 0.82 0.80 0.76 
Mann Whitney U test on Spectral 
Counts 0.84 0.88 0.89 0.87 0.84 0.82 
Modified Mann Whitney U test on 
Spectral Counts 0.84 0.88 0.89 0.87 0.83 0.82 
Mann Whitney U test on PPIDs 0.84 0.88 0.88 0.86 0.84 0.82 
 
Table S3.2  AUCs For Classical Tests Using the “Minimum Spectral Count/PPID across both 
cohorts” filter 
  Minimum Spectral Count/PPID across both cohorts 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.85 0.85 0.85 0.85 0.85 0.85 
Student's t-test on PPIDs 0.87 0.89 0.88 0.83 0.82 0.79 
Student's t-test log transformation on 
PPIDs 0.86 0.88 0.87 0.83 0.81 0.79 
Welch's t-test on PPIDs 0.87 0.88 0.86 0.83 0.81 0.84 
Welch's t-test log transformation on 
PPIDs 0.86 0.87 0.86 0.83 0.81 0.79 
Mann Whitney U test on Spectral 
Counts 0.84 0.84 0.84 0.84 0.84 0.84 
Modified Mann Whitney U test on 
Spectral Counts 0.84 0.84 0.84 0.84 0.84 0.84 
Mann Whitney U test on PPIDs 0.84 0.85 0.85 0.86 0.86 0.83 
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Table S3.3  AUCs For Combined Model (Classical Tests + Benchmark) Using the “Minimum 
Spectral Count/PPID at least one cohort” Filter 
  Minimum Spectral Count/PPID in at least one cohort 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.85 0.88 0.87 0.85 0.82 0.81 
Student's t-test on PPIDs 0.89 0.90 0.90 0.90 0.89 0.89 
Student's t-test log transformation on 
PPIDs 0.88 0.90 0.90 0.90 0.90 0.89 
Welch's t-test on PPIDs 0.89 0.90 0.90 0.89 0.90 0.89 
Welch's t-test log transformation on 
PPIDs 0.88 0.90 0.90 0.90 0.90 0.89 
Mann Whitney U test on Spectral 
Counts 0.85 0.89 0.90 0.90 0.90 0.89 
Modified Mann Whitney U test on 
Spectral Counts 0.85 0.89 0.90 0.90 0.90 0.90 
Mann Whitney U test on PPIDs 0.86 0.90 0.90 0.90 0.90 0.89 
 
Table S3.4  AUCs For Combined Model (Classical Tests + Benchmark) Using the “Minimum 
Spectral Count/PPID at across both cohorts” Filter 
  Minimum Spectral Count/PPID across both cohorts 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.85 0.88 0.87 0.85 0.82 0.81 
Student's t-test on PPIDs 0.89 0.90 0.88 0.83 0.82 0.79 
Student's t-test log transformation on 
PPIDs 0.88 0.90 0.90 0.90 0.90 0.89 
Welch's t-test on PPIDs 0.89 0.90 0.88 0.83 0.82 0.79 
Welch's t-test log transformation on 
PPIDs 0.88 0.90 0.90 0.90 0.90 0.90 
Mann Whitney U test on Spectral 
Counts 0.85 0.85 0.85 0.85 0.85 0.85 
Modified Mann Whitney U test on 
Spectral Counts 0.85 0.85 0.85 0.85 0.85 0.85 
Mann Whitney U test on PPIDs 0.86 0.86 0.87 0.87 0.87 0.86 
 
Table S3.5  AUCs For Empirical Bayes t-test Using the “Minimum Spectral Count/PPID in at 
least one cohort” filter 
  Minimum Spectral Count/PPID in at last one cohort 
Candidate Test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.85 0.88 0.87 0.85 0.82 0.81 
empirical Bayes on PPIDs 0.88 0.89 0.87 0.84 0.81 0.78 
empirical Bayes on PPIDs + missed 
PPID weighting 0.87 0.89 0.87 0.84 0.81 0.78 
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empirical Bayes on PPIDs + observed 
PPID weighting 0.88 0.89 0.87 0.84 0.81 0.78 
empirical Bayes on PPIDs + log 
normalization 0.86 0.88 0.87 0.83 0.81 0.78 
empirical Bayes on PPIDs + log 
normalization + missed PPID 
weighting 0.85 0.88 0.87 0.83 0.81 0.78 
empirical Bayes on PPIDs + log 
normalization + observed PPID 
weighting 0.86 0.88 0.87 0.83 0.81 0.78 
empirical Bayes on PPIDs + 
percentile normalization 0.85 0.88 0.87 0.83 0.81 0.78 
empirical Bayes on PPIDs + 
percentile normalization + missed 
PPID weighting 0.85 0.88 0.87 0.84 0.81 0.78 
empirical Bayes on PPIDs + 
percentile normalization + observed 
PPID weighting 0.85 0.87 0.86 0.83 0.81 0.78 
empirical Bayes on PPIDs + 
percentile+arcsine(sqrt) 
normalization 0.84 0.88 0.87 0.83 0.81 0.78 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
missed PPID weighting 0.84 0.89 0.87 0.84 0.81 0.78 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
observed PPID weighting 0.83 0.88 0.87 0.83 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization 0.86 0.87 0.86 0.83 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization + missed PPID 
weighting 0.86 0.87 0.86 0.83 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization + observed PPID 
weighting 0.87 0.87 0.86 0.83 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization + log 
transformation 0.87 0.88 0.86 0.83 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + missed PPID 
weighting 0.87 0.88 0.86 0.83 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + observed PPID 
weighting 0.86 0.87 0.86 0.83 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) 0.88 0.89 0.87 0.84 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
missed PPID weighting 0.88 0.89 0.87 0.84 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
observed PPID weighting 0.88 0.89 0.87 0.84 0.81 0.78 
96 
 
empirical Bayes on Spectral Counts 0.86 0.89 0.87 0.84 0.81 0.78 
 
 
 
Table S3.6  AUCs For Empirical Bayes t-test Using the “Minimum Spectral Count/PPID across 
both cohorts” filter 
  Minimum Spectral Count/PPID across both cohorts 
candidate test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.85 0.85 0.85 0.85 0.85 0.85 
empirical Bayes on PPIDs 0.88 0.89 0.88 0.83 0.82 0.79 
empirical Bayes on PPIDs + missed 
PPID weighting 0.87 0.89 0.88 0.83 0.81 0.79 
empirical Bayes on PPIDs + observed 
PPID weighting 0.88 0.89 0.88 0.83 0.82 0.79 
empirical Bayes on PPIDs + log 
normalization 0.86 0.88 0.87 0.83 0.81 0.78 
empirical Bayes on PPIDs + log 
normalization + missed PPID 
weighting 0.85 0.88 0.87 0.83 0.81 0.78 
empirical Bayes on PPIDs + log 
normalization + observed PPID 
weighting 0.86 0.88 0.87 0.83 0.81 0.78 
empirical Bayes on PPIDs + 
percentile normalization 0.85 0.88 0.87 0.83 0.81 0.78 
empirical Bayes on PPIDs + 
percentile normalization + missed 
PPID weighting 0.85 0.88 0.87 0.83 0.81 0.78 
empirical Bayes on PPIDs + 
percentile normalization + observed 
PPID weighting 0.85 0.87 0.87 0.82 0.81 0.78 
empirical Bayes on PPIDs + 
percentile+arcsine(sqrt) 
normalization 0.84 0.85 0.86 0.87 0.87 0.84 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
missed PPID weighting 0.84 0.84 0.85 0.86 0.86 0.83 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
observed PPID weighting 0.83 0.83 0.84 0.85 0.86 0.83 
empirical Bayes on PPIDs + max 
value normalization 0.86 0.87 0.86 0.83 0.81 0.79 
empirical Bayes on PPIDs + max 
value normalization + missed PPID 
weighting 0.86 0.87 0.86 0.82 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization + observed PPID 
weighting 0.87 0.87 0.86 0.83 0.81 0.79 
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empirical Bayes on PPIDs + max 
value normalization + log 
transformation 0.87 0.88 0.87 0.82 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + missed PPID 
weighting 0.87 0.88 0.87 0.82 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + observed PPID 
weighting 0.86 0.87 0.86 0.82 0.81 0.78 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) 0.88 0.89 0.88 0.83 0.82 0.79 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
missed PPID weighting 0.88 0.89 0.88 0.83 0.81 0.79 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
observed PPID weighting 0.88 0.89 0.87 0.83 0.82 0.79 
empirical Bayes on Spectral Counts 0.86 0.86 0.86 0.86 0.86 0.86 
 
Table S3.7  AUCs For Combined Model (Empirical Bayes t-test + Benchmark) Using the 
“Minimum Spectral Count/PPID in at least cohorts” filter 
  Minimum Spectral Count/PPID in at last one cohort 
candidate test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.85 0.88 0.87 0.85 0.82 0.81 
empirical Bayes on PPIDs 0.89 0.91 0.91 0.90 0.90 0.90 
empirical Bayes on PPIDs + missed 
PPID weighting 0.89 0.91 0.90 0.90 0.90 0.90 
empirical Bayes on PPIDs + observed 
PPID weighting 0.89 0.91 0.90 0.90 0.90 0.90 
empirical Bayes on PPIDs + log 
normalization 0.87 0.90 0.90 0.90 0.90 0.90 
empirical Bayes on PPIDs + log 
normalization + missed PPID 
weighting 0.87 0.90 0.90 0.90 0.90 0.90 
empirical Bayes on PPIDs + log 
normalization + observed PPID 
weighting 0.87 0.90 0.90 0.90 0.90 0.90 
empirical Bayes on PPIDs + 
percentile normalization 0.87 0.90 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + 
percentile normalization + missed 
PPID weighting 0.87 0.90 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + 
percentile normalization + observed 
PPID weighting 0.86 0.89 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + 
percentile+arcsine(sqrt) 
normalization 0.86 0.90 0.90 0.90 0.90 0.89 
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empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
missed PPID weighting 0.85 0.90 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
observed PPID weighting 0.85 0.89 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + max 
value normalization 0.89 0.90 0.90 0.90 0.89 0.89 
empirical Bayes on PPIDs + max 
value normalization + missed PPID 
weighting 0.89 0.90 0.90 0.90 0.89 0.89 
empirical Bayes on PPIDs + max 
value normalization + observed PPID 
weighting 0.89 0.90 0.90 0.89 0.89 0.89 
empirical Bayes on PPIDs + max 
value normalization + log 
transformation 0.89 0.91 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + missed PPID 
weighting 0.90 0.91 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + observed PPID 
weighting 0.89 0.90 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) 0.90 0.91 0.90 0.90 0.89 0.89 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
missed PPID weighting 0.90 0.91 0.90 0.90 0.89 0.89 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
observed PPID weighting 0.89 0.90 0.90 0.89 0.89 0.89 
empirical Bayes on Spectral Counts 0.86 0.90 0.90 0.90 0.90 0.90 
 
Table S3.8  AUCs For Combined Model (Empirical Bayes t-test + Benchmark) Using the 
“Minimum Spectral Count/PPID across both cohorts” filter 
  Minimum Spectral Count/PPID across both cohorts 
candidate test 0 5 10 15 20 25 
Fisher's exact test on Spectral Counts 
(Benchmark) 0.85 0.88 0.87 0.85 0.82 0.81 
empirical Bayes on PPIDs 0.89 0.91 0.91 0.90 0.90 0.90 
empirical Bayes on PPIDs + missed 
PPID weighting 0.89 0.91 0.90 0.90 0.90 0.90 
empirical Bayes on PPIDs + observed 
PPID weighting 0.89 0.91 0.90 0.90 0.90 0.90 
empirical Bayes on PPIDs + log 
normalization 0.87 0.90 0.90 0.90 0.90 0.90 
empirical Bayes on PPIDs + log 
normalization + missed PPID 
weighting 0.87 0.90 0.90 0.90 0.90 0.90 
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empirical Bayes on PPIDs + log 
normalization + observed PPID 
weighting 0.87 0.90 0.90 0.90 0.90 0.90 
empirical Bayes on PPIDs + 
percentile normalization 0.87 0.90 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + 
percentile normalization + missed 
PPID weighting 0.87 0.90 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + 
percentile normalization + observed 
PPID weighting 0.86 0.89 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + 
percentile+arcsine(sqrt) 
normalization 0.86 0.90 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
missed PPID weighting 0.85 0.90 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + 
percentile+arcsine normalization + 
observed PPID weighting 0.85 0.89 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + max 
value normalization 0.89 0.90 0.90 0.90 0.89 0.89 
empirical Bayes on PPIDs + max 
value normalization + missed PPID 
weighting 0.89 0.90 0.90 0.90 0.89 0.89 
empirical Bayes on PPIDs + max 
value normalization + observed PPID 
weighting 0.89 0.90 0.90 0.89 0.89 0.89 
empirical Bayes on PPIDs + max 
value normalization + log 
transformation 0.89 0.91 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + missed PPID 
weighting 0.90 0.91 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + max 
value normalization+log 
transformation + observed PPID 
weighting 0.89 0.90 0.90 0.90 0.90 0.89 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) 0.90 0.91 0.90 0.90 0.89 0.89 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
missed PPID weighting 0.90 0.91 0.90 0.90 0.89 0.89 
empirical Bayes on PPIDs + max 
value normalization+arcsine(sqrt) + 
observed PPID weighting 0.89 0.90 0.90 0.89 0.89 0.89 
empirical Bayes on Spectral Counts 0.86 0.90 0.90 0.90 0.90 0.90 
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Supplemental File 4.  Analysis Config File 
When run from the command line, IDPQuantify takes a single argument, “-
idpAnalysisConfigFile“, that specifies the pathway to analysis config file.  Users configure 
IDPQuantify using the “analysis_config” file.  Each line in the file contains an attribute and a 
value in the following format: 
-attribute_name “attribute_value” 
There are two types of attributes, Global Attributes and Per Statistical Run Attributes.  Global 
Attributes are only defined once.  Per Statistical Run Attributes are specified for each separate R-
script to be run.  When Per Statistical Run Attributes are declared in the analysis_config file the 
attribute name should be followed by a unique number.   
The attributes are as follows: 
Table S4.1 Global attribute name and values for „analysis_config‟ file 
Attribute Name Attribute Meaning 
resultOutputFilesRootFolder Pathway to folder where files will be created. 
resultFilesConfigFileFullPath Pathway to „files_config‟ file defining the two cohorts to be 
analyzed (See Supplemental File 5). 
resultSpcCntPerPepPerRep File name of file written by IDPQuantify listing the spectral 
counts per peptide per replicate. 
resultPPIDPerPepUnnorm File name of file written by IDPQuantify listing the PPID per 
peptide per replicate. 
resultPPIDObservedPerPepPerRep File name of file written by IDPQuantify listing the presence 
or absence (1 or 0) of at least one PPID observed per peptide 
per replicate. 
resultPPIDMissingPerPepPerRep File name of file written by IDPQuantify listing a “1” if 
IDPQuantify expected a PPID but could not find one per 
peptide per replicate.  Otherwise a “0” is listed. 
resultPPIDPerPep_missingPPIDWeight File name of file written by IDPQuantify containing the 
PPID per peptide weighted according to missing PPIDs. 
resultPPIDPerPep_foundPPIDWeight File name of file written by IDPQuantify containing the 
PPID per peptide weighted according to observed PPIDs. 
resultPPIDPerPep_unweighted File name of file written by IDPQuantify containing the 
PPID per peptide with no weighting. 
resultPPIDPerPepGrp_missingPPIDWeight File name of file written by IDPQuantify containing the 
PPID per peptide group weighted according to missing 
PPIDs. 
resultPPIDPerPepGrp_foundPPIDWeight File name of file written by IDPQuantify containing the 
PPID per peptide group weighted according to observed 
PPIDs. 
resultPPIDPerPepGrp_unweighted File name of file written by IDPQuantify containing the 
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PPID per peptide group with no weighting. 
resultSpcCntPerPepGrp File name of file written by IDPQuantify containing the 
Spectral Count per peptide group. 
resultPPIDCountPerPepGrp File name of file written by IDPQuantify containing the 
number of PPIDs observed per peptide group. 
resultPPIDPercentileNorm_foundPPIDWeight File name of file written by IDPQuantify containing the 
percentile normalized PPID per peptide group weighted 
according to observed PPIDs. 
resultPPIDPercentileNorm_missingPPIDWeight File name of file written by IDPQuantify containing the 
percentile normalized PPID per peptide group weighted 
according to missing PPIDs. 
resultPPIDPercentileNorm_noPPIDWeight File name of file written by IDPQuantify containing the 
percentile normalized PPID per peptide group with no 
weighting. 
resultSpcCntMinusPPIDPerPepGrp File name of file written by IDPQuantify containing the 
number of observed spectral counts, observed PPIDs, and 
missing PPIDs per peptide group per cohort. 
resultUniqPepSeqPerPepGrp File name of file written by IDPQuantify containing the 
number of unique peptide sequence per peptide group. 
resultNumPepSeqPerPepGrp File name of file written by IDPQuantify containing the 
number of total peptide sequences, including duplicate 
sequences, per peptide group.  Sequences are summed per 
replicate per peptide group. 
resultPhenotypeDataFileForRCohort The filename of the “phenotype.txt” data file used for R 
scripts that utilize the Limma package in R.  The pathway of 
this file is fed to each auto-run R script as one of the 
parameters. 
pathwayToRScriptExe Pathway to the RScript.exe executable. 
pathwayToIDPProtGrpToPepGrpFiles Pathway to IDPicker result file containing the protein group-
to-peptide group mapping. 
 
Table S4.2 Per Statistical Run Attribute Name and Values for „analysis_config‟ File 
Attribute Name Attribute Meaning 
resultRpvalsfile# File name of file name fed by IDPQuantify into R script for 
the resulting statistical test output file. 
resultRpvalsPPIDFile# Filename of quantitative data file to be fed into R script for 
statistical analysis.  Can be PPID or spectral count file 
generated by IDPQuantify (see Table S4.1).   
resultRpvalsfileTestLabel# Label to be used to describe this statistical test run in 
summary files and constructing output file names. 
resultPvalRScript# Pathway to R script to be run for this statistical run 
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Supplemental File 5.  Files Config file 
Users specify the location of IDPicker result files and spectral files (e.g. .RAW files) using the 
“files_config” file.  Each line in the file contains an attribute and a value in the following format: 
-attribute_name “attribute_value” 
There are two types of attributes, Global Attributes and Per Replicate Attributes.  Global 
Attributes are only defined once.  Per Replicate Attributes are specified for each separate MS run 
that is to be included in one of the two cohorts.  When Per Replicate Attributes are declared in 
the analysis_config file the attribute name should be followed by a unique number.   
Table S5.1 Global Attribute Name and Values for „files_config‟ File 
Attribute Name Attribute Meaning 
idpQuanCohort1 A comma-delimited list of numbers corresponding to the 
unique identifiers for each MS run in cohort 1.  The unique 
identifiers correspond to the “#” following the “Per 
Replicate” attributes for a given replicate (See Table S5.2). 
idpQuanCohort2 A comma-delimited list of numbers corresponding to the 
unique identifiers for each MS run in cohort 1.  The unique 
identifiers correspond to the “#” following the “Per 
Replicate” attributes for a given replicate (See Table S5.2). 
hardklorPathway Pathway to Hardklör executable. 
bullseyePathway Pathway to Bullseye executable. 
 
Table S5.2 Per Replicate Attribute Name and Values for „files_config‟ File 
Attribute Name Attribute Meaning 
idpXMLFile# Pathway to .idpXML for this replicate. 
hkFilePath# Pathway to Hardklör output file for this replicate.  If file does 
not exist, IDPQuantify will attempt to create it when run. 
bullseyeFoundFile# Pathway to Bullseye output file of MS/MS spectra with 
matching PPIDs for this replicate.  If file does not exist, 
IDPQuantify will attempt to create it when run. 
bullseyeMissedFile# Pathway to Bullseye output file of MS/MS spectra with 
missing PPIDs for this replicate.  If file does not exist, 
IDPQuantify will attempt to create it when run. 
spectralInputFile# Pathway to spectral file (e.g. .RAW) for this replicate. 
bullseyeMS2DataFile# Pathway to file containing MS/MS data for use when 
generating Bullseye files. 
hardklorMS2DataFile# Pathway to file containing MS data for use when generating 
Hardklör files. 
idpQuan# The pathway to the .idpQuan file generated by IDPQuantify 
containing PPIDs per peptide group. 
 
